EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

PERSONAL INFORMATION

Flora Peyvandi

WORK EXPERIENCE

2019- Present

Director

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO (Italy)

Rare Diseases Center

November 2021-June 2022

Scientific Director ad interim

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO (Italy)

2020- 2023

DIRECTOR

UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

Postgraduate Internal Medicine School

June 2017- Present

Director of the Unit of Internal Medicine - Hemostasis and Thrombosis (U.O.C di Medicina Generale Emostasi e Trombosi)

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Nov 2010

Member of the Board of Directors, Jun 2017 Co-chair of the Board of the Internal Medicine Department, Jun 2017

Member of the Scientific and Technical Committee, Jun 2017

April 2016- Present

PROFESSOR OF INTERNAL MEDICINE

UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

2013- 2016

Director of the Unit of non tumoral haematology and coagulopaties (U.O.C di Ematologia Non Tumorale e Coagulopatie

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

December 2010- Present

-Director of Department for diagnosis and treatment of coagulopathy

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

January 2001-December 2010

Associate medical director

FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO, UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

-Out-patient clinic for the diagnosis and treatment of rare bleeding disorders.

-Genetic counselling for coagulation disorders

-Out-patient clinic for the assistance to pregnancy for women affected with rare coagulation disorders and von Willebrand disease; reproductive assistance to HIV discordant couples affected with haemophilia

-Out-patient clinic for the diagnosis and treatment of thrombotic microangiopathies

January 1996-January 2001

RESEARCH FELLOW

Royal Free Hospital, London UK (United Kingdom)

1996- 2001 **RESEARCH FELLOW**
Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston (United States)

August 2011-July 2016 **Visiting Professor**
University College of London, Cancer Institute, London UK (United Kingdom)
project entitled Identification of genetic risk factors in autoimmune thrombotic thrombocytopenic purpura in collaboration with Prof. Samuel Machin (University College of London, London - UK) and Prof. Edward Tuddenham (Royal Free Hospital, London UK)

January 2005-April 2016 **ASSOCIATE PROFESSOR OF INTERNAL MEDICINE**
UNIVERSITA' DEGLI STUDI DI MILANO (Italy)
-Courses on i) Medical Clinic, ii) Medical Therapy, and iii) Internal Medicine at Post-graduate School in Internal Medicine, IRCCS Maggiore Hospital
-Courses on i) Molecular Biology applied to Hematology, ii) Methods and Notions in Haemostasis, iii) Methods and Notions in Immunology, iv) Clinic and Therapy of hemostasis disorders, and v) Internal Medicine at Post-graduate School of Hematology, IRCCS Maggiore Hospital
-Courses on i) Medical Clinic, ii) Medical Therapy, at School of Medicine, IRCCS Maggiore Hospital
-Courses on i) Biotechnological diagnostics, and ii) Cellular and Molecular Therapy at First degree course in Medical Biotechnologies and Molecular Medicine
-Member of the teaching staff and of the managing council of the Post-graduate school in Clinical and Laboratory Biomedical Sciences

January 2005-December 2007 **VISITING PROFESSOR**
Shiraz University of Medical Sciences, Nemazee Hospital, Shiraz - Iran (Iran)
courses on Molecular medicine, Congenital coagulopathies and thrombosis

EDUCATION AND TRAINING

October 2012- Present **HEMATOLOGIST SPECIALIST**
General Medical Council (United Kingdom)

February 2005-September 2012 **HEMATOLOGIST SPECIALIST**
GENERAL MEDICAL COUNCIL (United Kingdom)

2001- **RESEARCH DOCTORATE**
UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

2001- **PHD**
University of Maastricht, Maastricht ()

1996- **Specialization in Hematology**
UNIVERSITA' DEGLI STUDI DI MILANO (Italy)

1992- 1996 **HEMATOLOGY FELLOW**
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE DI MILANO (Italy)

1991- 1992 **RESIDENT IN MEDICINE**
San Paolo Hospital University of Milan (Italy)

1991- **DOCTOR OF MEDICINE**
Medical school of Università DEGLI sTUDI DI mILANO (Italy)

1990- 1991 **SCHOLARSHIP**
TRANSFUSION CENTER, SAN PAOLO UNIVERSITY HOSPITAL (Italy)

1987- 1990 **INTERNSHIP**

Department of Emergency and Department of Internal Medicine, San Paolo Hospital, Milan - Italy (Italy)

1982- **SCHOOL-LEAVING CERTIFICATE**

Secondary school education, Natural Science High School Nedaye Azadi, Tehran ()

ADDITIONAL INFORMATION

Expertise

MAJOR RESEARCH FIELDS:

- Clinical and laboratory aspects of hereditary coagulation disorders (thrombophilia and haemophilia)
- Genotype and phenotype characterisation of patients affected with rare coagulation disorders and von Willebrand disease
- Biochemical characterisation of mutant recombinant proteins causing rare coagulation disorders and von Willebrand disease
- Implementation of a International on-line database for the collection of clinical, laboratory and therapeutic data related to patients affected by rare bleeding disorders (RBDs: fibrinogen deficiency, Factor (F) II, FV, FVII, FV+FVIII, FX, FXI and FXIII) (www.rbdd.org)
- Development of new techniques for prenatal diagnosis in early stage of pregnancy in women carriers of haemophilia or affected by one of the other rare coagulation disorders
- Gene mutation, transcription, translation and transport analysis of FVIII in haemophilic patients with inhibitors
- Implementation of a novel thrombotic thrombocytopenic purpura database for the collection of clinical, genetic and therapeutic data (www.ttpdatabase.org)
- Basis research on molecular and immunological aspects of patients affected by autoimmune thrombotic thrombocytopenic purpura.
- Next-generation DNA sequencing to study the genetic predisposition to thrombotic and haemorrhagic disorders (myocardial infarction, deep vein thrombosis and haemophilia)

Publications

PUBLICATIONS

WITH NO IF: 27

TOTAL IF: 2889,652 (1996-2021)

Google Scholar H-index: 80

Scopus H-index: 69

Articles in peer-reviewed journals

2022

1. Leebeek FWG, Peyvandi F, Escobar MA, Tiede A, Castaman G, Wang M, Wynn T, Baptista J, Wang Y, Zhang J, Mellgard B, Ozen G. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood. 2022; doi: 10.1182/blood.2021014810.

2. Zanon E, Pasca S, Demartis F, Tagliaferri A, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Luciani M, Sottilotta G, Ricca I, Pollio B, Borchiellini A, Tosetto A, Peyvandi F, Frigo AC, Simioni P. Intracranial haemorrhage in haemophilia patients is still an open issue: The Final Results of the Italian EMO.REC Registry. J Clin Med. 2022;11:1969.

3. La Mura V, Gagliano N, Arnaboldi F, Sartori P, Procacci P, Denti L, Liguori E, Bitto N, Ristagno G, Latini R, Dondossola D, Salerno F, Tripodi A, Colombo M, Peyvandi F. Simvastatin prevents liver microthrombosis and sepsis induced coagulopathy in a rat model of endotoxemia. Cells. 2022;11:1148.

4. Buske C, Dreyling M, Alvarez-Larran A, Apperley J, Arcaini L, Besson C Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich HT, Foa R, Ghia P, da Silva MG, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian JJ, Kroger N, Moreau P, Passweg JR, Peyvandi F, Rea D, Ribera JM, Robak T, San-Miguel JF, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022;7:100403.

5. Miesbach W, Baghaei F, Boban A, Chowdary P, Coppens M, Hart DP, Jimenez-Yuste V, Klamroth R, Makris M, Noone D, Peyvandi F. Gene therapy of hemophilia: Hub centres should be

haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia. 2022; doi: 10.1111/hae.14546.

6. Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani AL. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines. 2022; 10:249.

7. Spena S, Cairo A, Pappalardo E, Gorski MM, Garagiola I, Hassan S, Gualtierotti R, Peyvandi F. Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A. Haemophilia. 2022;28:270-277.

8. Cairo A, Iorio MV, Spena S, Tagliabue E, Peyvandi F. Worldwide SARS-CoV-2 haplotype distribution in early pandemic. PLoS One. 2022;17:e0263705.

9. Klamroth R, Hayes G, Andreeva T, Gregg K, Suzuki T, Mitha IH, Hardesty B,Shima M, Pollock T, Slev P, Oldenburg J, Ozelo MC, Stieltjes N, Castet SM, Mahlangu J, Peyvandi F, Kazmi R, Schved JF, Leavitt AD, Callaghan M, Pan-Petesch B, Quon DV, Andrews J, Trinh A, Li M, Wong WY. Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther. 2022;33:432-441.

10. Indirli R, Bandera A, Valenti L, Ceriotti F, Di Modugno A, Tettamanti M, Gualtierotti R, Peyvandi F, Montano N, Blasi F, Costantino G, Resi V, Orsi E, Arosio M, Mantovani G, Ferrante E; COVID-19 Network Working Group. Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients. Eur J Clin Invest. 2022;52:e13753.

11. Pagliari MT, Rosendaal FR, Ahmadinejad M, Badiee Z, Baghaipour MR, Baronciani L, Benitez Hidalgo O, Bodo I, Budde U, Castaman G, Eshghi P, Goudemand J, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Marino R, Oldenburg J, Peake I, Santoro C, Schneppenheim R, Tiede A, Toogeh G, Tosetto A, Trossaert M, Yadegari H, Zetterberg EMK, Peyvandi F, Federici AB, Eikenboom J. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study. J Thromb Haemost. 2022;20:1106-1114 Jan 29. doi: 10.1111/jth.15658.

12. Pagliari MT, Baronciani L, Cordiglieri C, Colpani P, Cozzi G, Siboni SM, Peyvandi F. The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients. Haemophilia. 2022;28:292-300.

13. Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, Duerschmied D,Smyth SS, Parker WAE, Ajjan RA, Vilahur G, Badimon L, Berg JMT, Cate HT,Peyvandi F, Wang TT, Becker RC. Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol. 2022 doi:10.1038/s41569-021-00665-7.

14. Gualtierotti R, Tafuri F, Arcudi S, Solimeno PL, Acquati J, Landi L, Peyvandi F. Current and Emerging Approaches for Pain Management in Hemophilic Arthropathy. Pain Ther. 2022;11:1-15.

15. Rossio R, Tettamanti M, Nobili A, Harari S, Mannucci PM, Bandera A, Peyvandi F; COVID-19 network working group. Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment. Intern Emerg Med. 2022;17:303-306.

16. Ferrante E, Serban AL, Clerici M, Indirli R, Scalambrino E, Carosi G, Padovan L, Locatelli M, Arosio M, Peyvandi F, Mantovani G, Tripodi A. Evaluation of procoagulant imbalance in Cushing's syndrome after short- and long-term remission of disease. J Endocrinol Invest. 2022;45:9-16.

17. Rossio R, Cassin R, Lecchi A, La Marca S, Femia EA, Novembrino C, Siboni SM, Noto A, Reda G, Peyvandi F. Acquired hemophilia A and delta storage pool deficiency in a patient with indolent non-Hodgkin lymphoma. Platelets. 2022;33:168-170.

2021

18. Kenet G, Chen YC, Lowe G, Percy C, Tran H, von Drygalski A, Trossaert M, Reding M, Oldenburg J, Mingot-Castellano ME, Park YS, Peyvandi F, Ozelo MC, Mahlangu J, Quinn J, Huang M, Reddy DB, Kim B. Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study. J Clin Med. 2021;10:5959 (IF 4.242).

19. Cojutti PG, Zanon E, Pasca S, Pea F; Italian FXIII Study Group (... Peyvandi F...). Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Clin Pharmacokinet. 2021 Oct 31. doi: 10.1007/s40262-021-01079-x (IF 6.447).

20. Pagliari MT, Cairo A, Boscarino M, Mancini I, Pappalardo E, Bucciarelli P, Martinelli I, Rosendaal FR, Peyvandi F. Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS One. 2021;16:e0258675 (IF 3.240).

21. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, Bujanda L, Bouysran Y, Niemi ME, Palom A, Ellinghaus D, Khan A, Martinez-Bueno M, Rolker S, Amitrano S, Roade Tato L, Fava F; FinnGen; COVID-19 Host Genetics Initiative (HGI), Spinner CD, Prati D, Bernardo D, Garcia F, Darcis G, Fernandez-Cadenas I, Holter JC, Banales JM, Frithiof R, Kiryluk K, Duga S, Asselta R, Pereira AC, Romero-Gomez M, Nafria-Jimenez B, Hov JR, Migeotte I, Renieri A, Planas AM, Ludwig KU, Buti M, Rahmouni S, Alarcon-Riquelme ME, Schulte EC, Franke A, Karlsen TH, Valenti L, Zeberg H, Richards JB, Ganna A (... Peyvandi F...). Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021;131:e152386 (IF 14.808).

22. Cugno M, Macor P, Giordano M, Manfredi M, Griffini S, Grovetti E, De Maso L, Mellone S, Valenti L, Prati D, Bonato S, Comi G, Artoni A, Meroni PL, Peyvandi F. Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. J Autoimmun. 2021;124:102728 (IF 7.094).

23. Cugno M, Consonni D, Lombardi A, Bono P, Oggioni M, Uceda Renteria S, Pesatori AC, Castaldi S, Riboldi L, Bordini L, Nava CD, Ceriotti F, Torri A, Tafuri F, Ghigliazza G, Peyvandi F, Bandera A, Gori A. Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors. Vaccines (Basel). 2021;9:1011 (IF 4.422).

24. Miesbach W, Chowdary P, Coppens M, Hart DP, Jimenez-Yuste V, Klamroth R, Makris M, Noone D, Peyvandi F. Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia. 2021;27:967-973 (IF 4.287).

25. Eichinger S, Morange PE, Cattaneo M, Fretigny M, Rauch A, van Hylckama Vlieg A, Tregouet DA, Ruf W, Levi M, Paramo JA, van der Poll T, Kyrle PA, Garagiola I, Peyvandi F. The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. Hemasphere. 2021;5:e643 (IF 0).

26. Saccon E, Bandera A, Sciume M, Mikaeloff F, Lashari AA, Aliberti S, Sachs MC, Billi F, Blasi F, Gabriel EE, Costantino G, De Roberto P, Krishnan S, Gori A, Peyvandi F, Scudeller L, Canetta C, Lorson CL, Valenti L, Singh K, Baldini L, Fracchiolla NS; COVID-19 Network Working Group,, Neogi U. Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy. Microbiol Spectr. 2021;9:e0054921 (IF 7.171).

27. Bandera A, Nobili A, Tettamanti M, Harari S, Bosari S, Mannucci PM; COVID-19 Network Working Group (.. Peyvandi F...). Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Intern Emerg Med. 2021 doi: 10.1007/s11739-021-02797-7 (IF 3.397).

28. Kyriazopoulou E, Huet T, Cavalli G, Gori A, Kyprianou M, Pickkers P, Eugen-Olsen J, Clerici M, Veas F, Chatellier G, Kaplanski G, Netea MG, Pontali E,Gattorno M, Cauchois R, Kooistra E, Kox M, Bandera A, Beaussier H, Mangioni D, Dagna L, van der Meer JWM, Giamarellos-Bourboulis EJ, Hayem G; International Collaborative Group for Anakinra in COVID-19 (...Peyvandi F...). Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3:e690-e697 (IF 8.136).

29. Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. J Thromb Haemost. 2021:19:2554-2558. (IF 5.824)

30. Baronciani L, Peake I, Schneppenheim R, Goodeve A, Ahmadinejad M, Badiee Z, Baghaipour MR, Benitez O, Bodo I, Budde U, Cairo A, Castaman G, Eshghi P, Goudemand J, Hassenpflug W, Hoorfar H, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Marino R, Niksic N, Oyen F, Santoro C, Tiede A, Toogeh G, Tosetto A, Trossaert M, Zetterberg EMK, Eikenboom J, Federici AB, Peyvandi F. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Adv. 2021;5:2987-3001. (IF 6.686)

31. van Galen KPM, d'Oiron R, James P, Abdul-Kadir R, Kouides PA, Kulkarni R, Mahlangu JN, Othman M, Peyvandi F, Rotellini D, Winikoff R, Sidonio RF. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021;19:1883-1887. (IF 5.824)

32. Villa D, Ardolino G, Borellini L, Cogiamanian F, Vergari M, Savojardo V, Peyvandi F, Barbieri S. Subclinical myopathic changes in COVID-19. Neurol Sci. 2021;42:3973-3979. (IF 3.307)

33. Bonato S, Artoni A, Lecchi A, Schwarz G, La Marca S, Padovan L, Clerici M, Guadino C, Comi GP, Tripodi A, Peyvandi F. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. Haematologica. 2021;106:3021-3024 (IF 9.941)

34. COVID-19 Host Genetics Initiative (...Peyvandi F...). Mapping the human genetic architecture of COVID-19. Nature. 2021;600:472-477 (IF 49.962).

35. Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost. 2021;19:2112-2121. (IF 5.824)

36. Guipponi M, Masclaux F, Sloan-Bena F, Di Sanza C, Ozbek N, Peyvandi F, Menegatti M, Casini A, Malbora B, Neerman-Arbez M. A homozygous duplication of the *FGG* exon 8-intron 8 junction causes congenital afibrinogenemia. Lessons learned from the study of a large consanguineous Turkish family. Haematologica. 2021 doi: 10.3324/haematol.2021.278945. (IF 9.941)

37. Tripodi A, Rossi SC, Clerici M, Merati G, Scalambrino E, Mancini I, Baronciani L, Boscarino M, Monzani V, Peyvandi F. Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. Clin Chem Lab Med. 2021;59:1699-1708 (IF 3.694)

38. Krumb E, Fijnvandraat K, Makris M, Peyvandi F, Ryan A, Athanasopoulos A, Hermans C. Adoption of emicizumab (Hemlibra(R)) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia. 2021;27:736-743. (IF 4.287)

39. Weitz JI, Peyvandi F. International Society on Thrombosis and Haemostasis: Present and future. J Thromb Haemost. 2021;19:1599-1601. (IF 5.824)

40. Tripodi A, Scalambrino E, Chantarangkul V, Paoletti O, Clerici M, Novembrino C, Boscolo-Anzoletti M, Peyvandi F, Testa S. Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. Thromb Res. 2021 Jun 5;204:32-39.(IF 3.944)

41. Seidizadeh O, Ahmadinejad M, Homayoun S, Mannucci PM, Peyvandi F. Von Willebrand disease combined with coagulation defects in Iran. Blood Transfus. 2021;19:428-434 (IF 3.443)

42. O'Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Med. 2021,47:899-902. (IF 17.440)

43. Peyvandi F, Auerswald G, Austin SK, Liesner R, Kavakli K, Alvarez Roman MT, Millar CM. Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. Blood Rev. 2021 Apr 27:100833. doi:10.1016/j.blre.2021.100833. (IF 8.250)

44. Hassan S, Palla R, Valsecchi C, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Karimi M, Gouw SC, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET study group. Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia. 2021;27,e441-e449. (IF 4.287)

45. Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, Cugno M. Corrigendum to "Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19" [J. Autoimmun. 117C (2020) 102595]. J Autoimmun. 2021;120:102646. Erratum for: J Autoimmun. 2021;117:102595. (IF 7.094)

46. Corrao S, Nobili A, Natoli G, Mannucci PM, Perticone F, Pietrangelo A, Argano C; REPOSI Investigators (... Peyvandi F...). Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetol. 2021;58:1225-1236. (IF 4.280)

47. Sissa C, Al-Khaffaf A, Frattini F, Gaiardoni R, Mimiola E, Montorsi P, Melara B, Amato M, Peyvandi F, Franchini M. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci. 2021;60:103145. (IF 1.764)

48. Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv. 2021;5:2137-2141. (IF 6.686)

49. Rossio R, Pagliaro E, Artoni A, Baronciani L, Russo R, Mocellin MC, Lopez G, Peyvandi F. Pulmonary tumour thrombotic microangiopathy in a young man: clinical and immunohistochemical characterisation of a rare complication of gastric signet-ring cell carcinoma. Blood Transfus. 2021;19:506-509. (IF 3.443)

50. Passamonti SM, Artoni A, Carrabba G, Merati G, Abbattista M, Capecchi M, Castellani M, Marenghi C, Trombetta E, Giammattei L, Caroli M, Bucciarelli P, Scalambrino E, Peyvandi F, Martinelli I. Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study. J Thromb Thrombolysis. 2021;52:224-231. (IF 2.300)

51. Peyvandi F, Garagiola I, Mannucci PM. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. Blood Rev. 2021;49:100828. (IF

8.250)

52. Cugno M, Gualtierotti R, Casazza G, Tafuri F, Ghigliazza G, Torri A, Costantino G, Montano N, Peyvandi F. Mortality in Patients with COVID-19 on Renin Angiotensin System Inhibitor Long-Term Treatment: An Observational Study Showing that Things Are Not Always as They Seem. Adv Ther. 2021;38:2709-2716. (IF 3.845)

53. Cugno M, Berra S, Depetri F, Tedeschi S, Griffini S, Grovetti E, Caccia S, Cresseri D, Messa P, Testa S, Giglio F, Peyvandi F, Ardissino G. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2021; 32:1227-1235. (IF 10.121)

54. Spena S, Cordiglieri C, Garagiola I, Peyvandi F. Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein. Int J Mol Sci. 2021;22:2001. (IF 5.923)

55. Kaczmarek R, El Ekiaby M, Hart DP, Hermans C, Makris M, Noone D, O'Mahony B, Page D, Peyvandi F, Pipe SW, Sannie T, Schlenkrich U, Skinner MW, Srivastava A, Bok A, Pierce GF; World Federation of Hemophilia (WFH), European Association for Haemophilia, Allied Disorders (EAHAD), European Haemophilia Consortium (EHC), U.S. National Hemophilia Foundation (NHF). Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia. 2021;27:515-518. (IF 4.287)

56. Oldenburg J, Tran H, Peyvandi F, Nunez R, Trask P, Chebon S, Mahlangu JN, Lehle M, Jimenez-Yuste V, von Mackensen S. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021; 27:398-407. (IF 4.287)

57. Peyvandi F, Miri S, Garagiola I. Immune Responses to Plasma-Derived Versus Recombinant FVIII Products. Front Immunol. 2021;11:591878. (IF 7.561)

58. Ghirardello S, Lecchi A, Artoni A, Panigada M, Aliberti S, Scalambrino E, La Marca S, Boscarino M, Gramegna A, Properzi P, Abruzzese C, Blasi F, Grasselli G, Mosca F, Tripodi A, Peyvandi F. Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study. Thromb Haemost. 2021;121:1087-1096. (IF 5.249)

59. Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lammle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas M, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: An International Working Group Consensus Report. Blood. 2021; 137:1855-1861. (IF 22.113)

60. Casini A, von Mackensen S, Santoro C, Djambas Khayat C, Belhani M, Ross C, Dorgalaleh A, Naz A, Unal E, Abdelwahab M, Dupuis Lozeron E, Trillot N, Susen S, Peyvandi F, de Moerloose P. Clinical phenotype, fibrinogen supplementation and health-related quality of life in patients with afibrinogenemia. Blood. 2021; 137:3127-3136. (IF 22.113)

61. Seidizadeh O, Peyvandi F, Mannucci PM. Von Willebrand disease type 2N: an update. J Thromb Haemost. 2021; 19:909-916. (IF 5.824)

62. Ross CR, Subramanian S, Navarro-Puerto J, Subramanian K, Kalappanavar NK, Khayat CD, Acharya SS, Peyvandi F, Rucker K, Liang W, Vilardell D, Trimm S, Ayguasanosa J. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia. Thromb Res. 2021;199:110-118. (IF 3.944)

63. Ierardi AM, Gaibazzi N, Tuttolomondo D, Fusco S, La Mura V, Peyvandi F, Aliberti S, Blasi F, Cozzi D, Carrafiello G, De Filippo M. Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. Radiol Med. 2021; 126:722-728. (IF 3.469)

64. Valenti L, Griffini S, Lamorte G, Grovetti E, Uceda Renteria SC, Malvestiti F, Scudeller L, Bandera A, Peyvandi F, Prati D, Meroni P, Cugno M. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19. J Autoimmun. 2021; 117.102595. (IF 7.094)

65. Capecchi M, Scalambrino E, Griffini S, Grovetti E, Clerici M, Merati G, Chantarangkul V, Cugno M, Peyvandi F, Tripodi A. Relationship between thrombin generation parameters and prothrombin fragment 1 + 2 plasma levels. Int J Lab Hematol. 2021;43:e248-e251. (IF 2.877)

66. Pepe J, Agosti P, Cipriani C, Tettamanti M, Nobili A, Colangelo L, Santori R, Cilli M, Minisola S; Reposi investigators. Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) (... Peyvandi F...). Endocrine. 2021;71:484-493. (IF 3.633)

67. Biguzzi E, Siboni SM, le Cessie S, Baronciani L, Rosendaal FR, van Hylckama Vlieg A, Peyvandi F. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al. J Thromb Haemost. 2021;19:310. (letter 5.824:5= 1.164)

68. Tripodi A, Spina L, Pisani LF, Padovan L, Cavallaro F, Chantarangkul V, Valsecchi C, Peyvandi F, Vecchi M. Anti-TNF- Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021;27:1901-1908. (IF 5.325)

69. Martinelli I, Ciavarella A, Abbattista M, Aliberti S, De Zan V, Folli C, Panigada M, Gori A, Artoni A, Ierardi AM, Carrafiello G, Monzani V, Grasselli G, Blasi F, Peyvandi F. Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med. 2021;16:1223-1229. (IF 3.397)

70. Indirli R, Ferrante E, Scalambrino E, Profka E, Clerici M, Lettera T, Serban AL, Vena W, Pizzocaro A, Bonomi M, Cangiano B, Carosi G, Mazziotti G, Persani L, Lania A, Arosio M, Peyvandi F, Mantovani G, Tripodi A. Procoagulant imbalance in Klinefelter syndrome assessed by thrombin generation assay and whole blood thromboelastometry. J Clin Endocrinol Metab. 2021;106:e1660-e1672. (IF 5.958)

71. Valsecchi C, Gobbi M, Beeg M, Adams T, Castaman G, Schiavone L, Huntington JA, Peyvandi F. Characterization of the neutralizing anti-emicizumab antibody in a patient with haemophilia A and inhibitor. J Thromb Haemost. 2021; 19:711-718. (IF 5.824)

72. Pipe SW, Kruse-Jarres R, Mahlangu JN, Pierce GF, Peyvandi F, Kuebler P, De Ford C, Sanabria F, Ko RH, Chang T, Hay CRM. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021;19 (Suppl 1):21-31. (IF 5.824)

73. Peyvandi F, Mahlangu JN, Pipe SW, Hay CRM, Pierce GF, Kuebler P, Kruse-Jarres R, Shima M. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021;19 (Suppl 1):32-41. (IF 5.824)

74. Djambas Khayat C, Lohade S, D'Souza F, Shamanur LG, Zekavat OR, Kruzhkova I, Schwartz B, Solomon C, Knaub S, Peyvandi F. Efficacy and safety of fibrinogen concentrate for on-demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency. Haemophilia. 2021;27:283-292. (IF 4.287)

75. Peyvandi F, Miri S, Bucciarelli P, Valsecchi C, Schiavone L, Boscarino M, Palla R, Mannucci PM, Rosendaal FR; SIPPET group. IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Br J Haematol. 2021; 192:621-625. (IF 6.998)

76. Abbattista M, Ciavarella A, Capecchi M, Tantardini F, Gramegna A, Lombardi R, Scaramellini N, Peyvandi F, Martinelli I. Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy. Infect Dis (Lond). 2021; 53:226-229. (IF 3.404)

77. Ciavarella A, Erra R, Abbattista M, Iurlaro E, Boscolo-Anzoletti M, Ossola MW, Mosca F, Ferrazzi E, Peyvandi F, Martinelli I. Hemostasis in pregnant women with COVID-19. Int J Gynecol Obstet. 2021; 152:268-269. (IF 3.561)

78. Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, Novembrino C, Boscolo Anzoletti M, De Zan V, Pagliari MT, Gualtierotti R, Aliberti S, Panigada M, Grasselli G, Blasi F, Peyvandi F. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021; 19:513-521. (IF 5.824)

79. Bozzi G, Mangioni D, Minoia F, Aliberti S, Grasselli G, Barbetta L, Castelli V, Palomba E, Alagna L, Lombardi A, Ungaro R, Agostoni C, Baldini M, Blasi F, Cesari M, Costantino G, Fracanzani AL, Montano N, Monzani V, Pesenti A, Peyvandi F, Sottocorno M, Muscatello A, Filocamo G, Gori A, Bandera A. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. J Allergy Clin Immunol. 2021; 147:561-566. (IF 10.793)

80. Pagliari MT, Boscarino M, Cairo A, Mancini I, Martinelli I, Bucciarelli P, Rossi F, Rosendaal FR, Peyvandi F. ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. Thromb Res. 2021;197:132-137. (IF 3.944)

81. Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Lonati P, Grossi C, Borghi MO, Novembrino C, Boscolo M, Uceda Renteria SC, Valenti L, Lamorte G, Manunta M, Prati D, Pesenti A, Blasi F, Costantino G, Gori A, Bandera A, Tedesco F, Peyvandi F. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J Autoimmun. 2021; 116:102560. (IF 7.094)

82. Garagiola I, Mortarino M, Siboni SM, Boscarino M, Mancuso ME, Biganzoli M, Santagostino E, Peyvandi F. X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers. Eur J Hum Genet. 2021;29:241-249. (IF 4.246)

83. Biguzzi E, Siboni SM, le Cessie S, Baronciani L, Rosendaal FR, van Hylckama Vlieg A, Peyvandi F. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by

von Willebrand disease. J Thromb Haemost. 2021;19:96-106. (IF 5.824)

84. De Vincentis A, Vespasiani-Gentilucci U, Costanzo L, Novella A, Cortesi L, Nobili A, Mannucci PM, Incalzi RA; REPOSI Investigators (...Peyvandi F...). The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age Ageing. 2021;50:498-504. (IF 10.668)

85. Peyvandi F, Artoni A, Novembrino C, Aliberti S, Panigada M, Boscarino M, Gualtierotti R, Rossi F, Palla R, Martinelli I, Grasselli G, Blasi F, Tripodi A. Hemostatic alterations in COVID-19. Haematologica. 2021;106:1472-1475 (letter 9.941:5= 1.988)

86. Ierardi AM, Coppola A, Fusco S, Stellato E, Aliberti S, Andrisani MC, Vespro V, Arrichiello A, Panigada M, Monzani V, Grasselli G, Venturini M, Rehani B, Peyvandi F, Pesenti A, Blasi F, Carrafiello G. Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound? J Ultrasound. 2021;24:165-173. (IF 0)

87. Argano C, Scichilone N, Natoli G, Nobili A, Corazza GR, Mannucci PM, Perticone F, Corrao S; REPOSI Investigators (...Peyvandi F...). Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. Intern Emerg Med. 2021; 16:389-400. (IF 3.397)

88. Rossio R, Colombo G, Piconi S, Peyvandi F. Adult-Onset Still Disease After Human Herpesvirus 6 Infection in an Elderly Patient: A Case Report. J Clin Rheumatol. 2021;27(8S):S466-468 (IF 3.517)

2020

89. Konkle B, Pierce G, Coffin D, Naccache M, Clark RC, George L, Iorio A, O'Mahony B, Pipe S, Skinner M, Watson C, Peyvandi F, Mahlangu J; ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020;18:3074-3077 (IF 4.157).

90. Pasta G, Mancuso ME, De Felice F, Seuser A, Annunziata S, Peyvandi F, Santagostino E, Mosconi M, Seuser A. Handwriting Analysis in Children and Adolescents with Hemophilia: A Pilot Study. J Clin Med. 2020;9:3663 (IF 3.303).

91. Mancini I, Giacomini E, Pontiggia S, Artoni A, Ferrari B, Pappalardo E, Gualtierotti R, Trisolini SM, Capria S, Facchini L, Codeluppi K, Rinaldi E, Pastore D, Campus S, Caria C, Caddori A, Nicolosi D, Giuffrida G, Agostini V, Roncarati U, Mannarella C, Fragasso A, Podda GM, Birocchi S, Cerbone AM, Tufano A, Menna G, Pizzuti M, Ronchi M, De Fanti A, Amarri S, Defina M, Bocchia M, Ceru S, Gattillo S, Rosendaal FR, Peyvandi F. The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. J Clin Med. 2020;9:3379. (IF 3.303)

92. Aliberti S, Amati F, Pappalettera M, Di Pasquale M, D'Adda A, Mantero M, Gramegna A, Simonetta E, Oneta AM, Privitera E, Gori A, Bozzi G, Peyvandi F, Minoia F, Filocamo G, Abbruzzese C, Vicenzi M, Tagliabue P, Alongi S, Blasi F. COVID-19 multidisciplinary high dependency unit: the Milan model. Respir Res. 2020;21:260. (IF 3.924)

93. Ghirardello S, Raffaeli G, Scalambrino E, Cortesi V, Roggero P, Peyvandi F, Mosca F, Tripodi A. Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. Front Pediatr. 2020; doi:10.3389/fped.2020.00510. (IF 2.634)

94. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18:2486-2495. (IF 4.157)

95. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18:2503-2512. (IF 4.157)

96. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18:2496-2502. (IF 4.157)

97. Tripodi A, Chantarangkul V, Novembrino C, Scalambrino E, Boscolo-Anzoletti M, Clerici M, Rossi F, Peyvandi F. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. Clin Chem Lab Med. 2020; 59:365-371. (IF 3.595)

98. Ferrari B, Peyvandi F. How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood. 2020; 136:2125-2132. (IF 17,794)

99. Noone D, O'Mahony B, Peyvandi F, Makris M, Bok A. Evolution of Haemophilia Care in Europe: 10 years of the principles of care. Orphanet J Rare Dis. 2020;15:184. (IF 3.523)

100. Costantino G, Peyvandi F, Montano N, Agostoni C. Romeo and Juliet: Revisited (at the time of COVID-19). Eur J Intern Med. 2020;81:94 (letter IF 4.329:5= 0.866)

101. Bandera A, Aliberti S, Gualtierotti R, Baldini M, Blasi F, Cesari M, Costantino G, Fracanzani AL, Gori A, Montano N, Monzani V, Nobili A, Peyvandi F, Pesenti A, Prati D, Valenti L, Fusetti G, Scudeller L, Bosari S; COVID19 Network. COVID-19 network: the response of an Italian reference Institute to research challenges about a new pandemia. Clin Microbiol Infect. 2020:26:1576-1578. (IF 7.117)

102. La Mura V, Artoni A, Martinelli I, Rossio R, Gualtierotti R, Ghigliazza G, Fusco S, Ierardi AM, Andrisani MC, Carrafiello G, Peyvandi F. Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report. Am J Gastroenterol. 2020:115:1140-1142. (IF 10.171)

103. Capecchi M, Mocellin C, Abbruzzese C, Mancini I, Prati D, Peyvandi F. Dramatic presentation of acquired TTP associated with COVID-19. Haematologica. 2020; 105:e540. (IF 7.116)

104. Biguzzi E, Siboni SM, Peyvandi F. How I treat gastro-intestinal bleeding in congenital and acquired von Willebrand disease. Blood. 2020; 136:1125-1133. (IF 17.543)

105. Szederjesi A, Baronciani L, Budde U, Castaman G, Colpani P, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Patzke J, Bodo I. Comparison of von Willebrand factor platelet-binding activity assays: ELISA overreads type 2B with loss of HMW multimers. J Thromb Haemost. 2020; 18:2513-2523. (IF 4.157)

106. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F, Kassens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A, Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A, Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julia A, Pesenti A, Voza A, Jimenez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C, Cea C, Solier A, Pestana D, Muniz-Diaz E, Sandoval E, Paraboschi EM, Navas E, Garcia Sanchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Blasi F, Tellez L, Blanco-Grau A, Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara H, ElAbd H, My I, Galvan-Femenia I, Martin J, Erdmann J, Ferrusquia-Acosta J, Garcia-Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro L, Scudeller L, Mesonero F, Roade L, Ruhlemann MC, Schaefer M, Carrabba M, Riveiro-Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M, D'Angio M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, Ciccarelli M, Rodriguez-Gandia M, Bocciolone M, Miozzo M, Montano N, Braun N, Sacchi N, Martinez N, Ozer O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P, Rodrigues PM, Blandino Ortiz A, de Cid R, Ferrer R, Gualtierotti R, Nieto R, Goerg S, Badalamenti S, Marsal S, Matullo G, Pelusi S, Juzenas S, Aliberti S, Monzani V, Moreno V, Wesse T, Lenz TL, Pumarola T, Rimoldi V, Bosari S, Albrecht W, Peter W, Romero-Gomez M, D'Amato M, Duga S, Banales JM, Hov JR, Folseraas T, Valenti L, Franke A, Karlsen TH; Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020; 383:1522-1534. (IF 74.699)

107. Peyvandi F, Lillicrap D, Mahlangu J, McLintock C, Pasi KJ, Pipe SW, Scales W, Srivastava A, VandenDriessche T. Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Res Pract Thromb Haemost. 2020;4:644-651. (IF 4.379)

108. Peyvandi F, Berger K, Seitz R, Hilger A, Hecquet ML, Wierer M, Buchheit KH, O Mahony B, Bok A, Makris M, Mansmann U, Schramm W, Mannucci PM. Kreuth V initiative: European consensus proposals for treatment of haemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica. 2020: 105:2038-2043. (IF 7.116)

109. Konkle BA, Coffin D, Pierce GF, Clark C, George L, Iorio A, Mahlangu J, Naccache M, O'Mahony B, Peyvandi F, Pipe S, Quartel A, Sawyer EK, Skinner MW, Tortella B, Watson C, Winburn I; Members of the WFH Gene Therapy Registery Steering Committee. World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 2020; 26:563-564. (IF 2.990)

110. Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, Peyvandi F. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146:215-2117. (letter IF 10.228:5=2.045)

111. Tosetto A, Badiee Z, Baghaipour MR, Baronciani L, Battle J, Berntorp E, Bodo I, Budde U, Castaman G, Eikenboom JCJ, Eshghi P, Ettorre C, Goodeve A, Goudemand J, Charles Richard Morris H, Hoorfar H, Karimi M, Keikhaei B, Lassila R, Leebeek FWG, Lopez Fernandez MF, Mannucci PM, Mazzucconi MG, Morfini M, Oldenburg J, Peake I, Parra Lopez R, Peyvandi F, Schneppenheim R, Tiede A, Toogeh G, Trossaert M, Zekavat O, Zetterberg EMK, Federici AB.

Bleeding symptoms in patients diagnosed as type 3 Von Willebrand Disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost. 2020; 18:2145-2154 (IF 4.157)

112. Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, Ossola M, Lombardi A, Blasi F, Mosca F, Peyvandi F. Pulmonary embolism in a young pregnant woman with COVID-19. Thromb Res. 2020;191:36-37. (letter IF 2.869:5= 0.573)

113. Ciavarella A, Peyvandi F, Martinelli I. Where do we stand with antithrombotic prophylaxis in patients with COVID-19? Thromb Res. 2020;191:29. (IF 2.869)

114. Roose E, Schelpe AMB, Tellier E, Sinkovits G, Joly BS, Dekimpe C, Kaplanski G, Le Besnerais M, Mancini I, Falter DT, von Auer C, Feys HB, Reti M, Rossmann H, Vandenbulcke A, Pareyn I, Voorberg J, Greinacher A, Benhamou Y, Deckmyn H, Fijnheer RR, Prohaszka Z, Peyvandi F, Lammle B, Coppo P, De Meyer S, Veyradier A, Vanhoorelbeke K. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood. 2020; 136:353-361. (IF 17.543)

115. Raffaeli G, Tripodi A, Manzoni F, Scalambrino E, Pesenti N, Amodeo I, Cavallaro G, Villamor E, Peyvandi F, Mosca F, Ghirardello S. Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth? Transfusion. 2020;60:1069-1077. (IF 2.800)

116. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020; 18: 1738-1742. (IF 4.157)

117. Chantarangkul V, Peyvandi F, Tripodi A; Investigating Group. Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. Thromb Res. 2020; 190:20-25. (IF 2.869)

118. Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut. 2020; 69:1148-1149. (letter IF 19.819:5= 3.963)

119. Agosti P, Mancini I, Gianniello F, Bucciarelli P, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Carbone C, Peyvandi F; Italian Group of TTP Investigators. Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura. Eur J Intern Med. 2020;75:79-83. (IF 4.329)

120. Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18: 1242-1255. (IF 4.157)

121. Abbattista M, Gianniello F, Novembrino C, Clerici M, Artoni A, Bucciarelli P, Capecchi M, Peyvandi F, Martinelli I. Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. Lancet Haematol. 2020; 7:e320-e328. (IF 10.406)

122. Stufano F, Baronciani L, Bucciarelli P, Boscarino M, Colpani P, Pagliari MT, Peyvandi F. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease. Haemophilia. 2020; 26:298-305. (IF 2.990)

123. Scalambrino E, Padovan L, Chantarangkul V, Clerici M, Artoni A, Peyvandi F, Tripodi A. Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study. Int J Lab Hematol. 2020; 4:e128-e131. (IF 2.141)

124. Shapiro AD, Menegatti M, Palla R, Boscarino M, Roberson C, Lanzi P, Bowen J, Nakar C, Janson IA, Peyvandi F. An international registry of patients with plasminogen deficiency (HISTORY). Haematologica. 2020;105(3):554-561. (IF 7.116)

125. Negri L, Buzzi A, Aru AB, Cannavo A, Castegnaro C, Fasulo MR, Lassandro G, Rocino A, Santoro C, Sottilotta G, Giordano P, Mazzucconi MG, Mura R, Peyvandi F, Delle Fave A. Perceived well-being and mental health in haemophilia. Psychol Health Med. 2020;1:1-11. (IF 1.706)

126. Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Subramanian K, D'Souza F, Viswabandya A, Hoorfar H, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020;18:815-824. (IF 4.157)

127. Lecchi A, La Marca S, Femia EA, Lenz A, Boeckelmann D, Artoni A, Peyvandi F, Zieger B. Novel variant in HPS3 gene in a patient with Hermansky Pudlak syndrome (HPS) type 3. Platelets. 2020;31:960-963 (3.378)

128. Mancuso ME, Linari S, Santagostino E, Bartolozzi D, D'Ambrosio R, Borghi M, Lampertico P,

Peyvandi F, Castaman G, Aghemo A. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study. Liver Int. 2020;40:1062-1068. (IF 5.175)

129. Tripodi A, Raffaeli G, Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Cavallaro G, Peyvandi F, Mosca F, Ghirardello S. Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. Thromb Res. 2020;185:96-101. (IF 2.869)

130. Kalot MA, Al-Khatib M, Connell NT, Flood V, Brignardello-Petersen R, James P, Mustafa RA; VWD working group (... Peyvandi F...). An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia. 2020;26:106-116. (IF 2.990)

131. Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. J Thromb Thrombolysis. 2020;49:413-419. (IF 2.054)

132. Paraboschi EM, Khera AV, Merlini PA, Gigante L, Peyvandi F, Chaffin M, Menegatti M, Busti F, Girelli D, Martinelli N, Olivieri O, Kathiresan S, Ardissino D, Asselta R, Duga S. Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease. Haematologica. 2020;105:e365-e369. (IF 7.116)

133. Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18:479-484. (IF 4.157)

134. Agosti P, Mancini I, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Peyvandi F; Italian Group of TTP Investigators. The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. Thromb Res. 2020;187:197-201. (IF 2.869)

135. Castaman G, Santoro C, Coppola A, Mancuso ME, Santoro RC, Bernardini S, Pugliese FR, Lubrano R, Golato M, Tripodi A, Rocino A, Santagostino E; ad hoc Working Group, Biasoli C, Borchiellini A, Catalano A, Contino L, Coluccia A, Cultrera D, De Cristofaro R, Di Minno G, Fabbri A, Franchini M, Gamba G, Giuffrida AC, Gresele P, Giampaolo A, Hassan HJ, Luciani M, Marchesini E, Marino R, Mazzucconi MG, Molinari AC, Morfini M, Notarangelo LD, Peccarisi L, Peyvandi F, Pollio B, Rivolta GF, Ruggieri MP, Sargentini V, Schiavoni M, Sciacovelli L, Serino ML, Siragusa S, Tagliaferri A, Testa S, Tosetto A, Zampogna S, Zanon E. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020;18:143-151. (IF 3.662)

136. Riva S, Mancini I, Maino A, Ferrari B, Artoni A, Agosti P, Peyvandi F. Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura. Haematologica. 2020; 105:1957-1962. (IF 7.116)

137. Paraboschi EM, Menegatti M, Rimoldi V, Borhany M, Abdelwahab M, Gemmati D, Peyvandi F, Duga S, Asselta R. Profiling the mutational landscape of coagulation factor V deficiency. Haematologica. 2020;105:e180-e185. (IF 7.116)

138. Proietti M, Agosti P, Lonati C, Corrao S, Perticone F, Mannucci PM, Nobili A, Harari S; REPOSI Investigators [...Peyvandi F...]. Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. J Am Med Dir Assoc. 20:1313-1317.e9 (IF 4,899).

139. Baronciani L, Peyvandi F. How we make an accurate diagnosis of von Willebrand disease. Thromb Res. 2020;196:579-589.

2019

140. Menegatti M, Biguzzi E, Peyvandi F. Management of rare acquired bleeding disorders. Hematology Am Soc Hematol Educ Program. 2019: 2019(1):80-87. (IF 2.497)

141. Peri AM, Rossio R, Tafuri F, Benzecry V, Grancini A, Reda G, Bandera A, Peyvandi F. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia. Ann Hematol. 2019;98:2847-2849. (letter IF 2.850:5= 0,57).

142. Tripodi A, Chantarangkul V, Padovan L, Clerici M, Scalambrino E, Peyvandi F. Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. J Thromb Thrombolysis. 2019; 49:413-419. (IF 2.941)

143. Fioredda F, Cappelli E, Mariani A, Beccaria A, Palmisani E, Grossi A, Ceccherini I, Vene R, Micalizzi C, Calvillo M, Pierri F, Mancini I, Peyvandi F, Corsolini F, Dufour C, Miano M. Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil. Blood Adv. 2019;3:3432-3435.

144. Agosti P, Mancini I, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Peyvandi F; Italian Group of TTP Investigators. The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age. Thromb Res. 2019;187: 197-201 (IF3.266).

145. Valsecchi C, Mirabet M, Mancini I, Biganzoli M, Schiavone L, Faraudo S, Mane-Padros D, Giles D, Serra-Domenech J, Blanch S, Trisolini SM, Facchini L, Rinaldi E, Peyvandi F. Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity. Thromb Haemost. 2019;119:1767-1772. (IF 4.733)

146. Rossio R, Ardoino I, Franchi C, Nobili A, Mannucci PM, Peyvandi F; REPOSI Investigators. Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register. Intern Emerg Med. 2019; 14:1347-1352. (IF 2.335).

147. Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL. Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. Liver Int. 2019; 39:2309-2316 (IF 5.542).

148. Peyvandi F, Garagiola I, Boscarino M, Ryan A, Hermans C, Makris M. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia. 2019; 25:946-952 (IF 3.590).

149. Moffat KA, Kiencke V, Blanco AN, McLintock C, Peyvandi F, de Maat MPM, Adams MJ, Angchaisuksiri P, Nair S, Tsuda H, Haddad M, Renne T, Clark RC, Ross MT. International Society on Thrombosis and Haemostasis core curriculum project: core competencies in laboratory thrombosis and hemostasis. J Thromb Haemost. 2019; 17:1848-1859 (IF 4.662).

150. Peyvandi F. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Reply. J Thromb Haemost. 2019;17:1405-1406 (letter IF 4.662:5= 0.932).

151. Peyvandi F, Tavakkoli F, Frame D, Quinn J, Kim B, Lawal A, Lee MC, Wong WY. Burden of mild haemophilia A: Systematic literature review. Haemophilia. 2019; 25:755-763 (IF 3.590).

152. Peyvandi F, Garagiola I. Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia. Haemophilia. 2019; 25:738-746 (IF 3.590).

153. De Cristofaro R, Sacco M, Lancellotti S, Berruti F, Garagiola I, Valsecchi C, Basso M, Di Stasio E, Peyvandi F. Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects. TH Open. 2019;3:e123-e131.

154. Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Rev. 2019;38:100572 (IF 6,125).

155. Weyand AC, Grzegorski SJ, Rost MS, Lavik KI, Ferguson AC, Menegatti M, Richter CE, Asselta R, Duga S, Peyvandi F, Shavit JA. Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. Blood Adv. 2019;3:1670-1680

156. Oldenburg J, Hay CRM, Jimenez-Yuste V, Peyvandi F, Schved JF, Szamosi J, Winding B, Lethagen S. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study. BMJ Open. 2019;9:e028012 (IF 2,376).

157. Novembrino C, Boscolo Anzoletti M, Mancuso ME, Shinohara S, Peyvandi F. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia. 2019;25:521-526 (IF 3,590).

158. Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue FVIII replacement to secure haemostasis in a patient with haemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019:104:e380-e382 (IF 7,570).

159. Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators. Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopaenic Purpura: Fourteen Years of the Milan TTP Registry. Thromb Haemost. 2019;119:695-704 (IF 4,733).

160. Maino A, Algra A, Peyvandi F, Rosendaal FR, Siegerink B. Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study. BMC Cardiovasc Disord. 2019;19:55 (IF 1,947).

161. Gorski MM, Lecchi A, Femia EA, La Marca S, Cairo A, Pappalardo E, Lotta LA, Artoni A, Peyvandi F. Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects. Haematologica 2019;104:2084-2090 (IF 7,570).

162. Paraboschi EM, Menegatti M, Peyvandi F, Duga S, Asselta R. Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency. Int J Mol Sci. 2019;20:e910 (IF 4,183).

163. Ferrari B, Cairo A, Pagliari MT, Mancini I, Arcudi S, Peyvandi F. Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura. J Thromb Haemost. 2019; 17:666-669 (IF 4,662).

164. Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jimenez-Yuste V, Konigs C, Iorio A, Federici AB. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfus. 2019;17:391-398 (IF 3,352)

165. Hubbard AR, Thelwell C, Rigsby P; subcommittee on factor VIII factor IX, rare coagulation disorders [...Peyvandi F...]. Establishment of the WHO 2nd International Standard Factor V, plasma (16/374): Communication from the SSC of the ISTH. J Thromb Haemost. 2019;17:695-697 (IF 4,662)

166. Repesse Y, Costa C, Palla R, Farrokhi Moshai E, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S. Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A. Haematologica. 2019;104:e369-e372 (IF 7,570)

167. Tripodi A, Primignani M, Badiali S, de Ruberto F, Granelli P, Tosetti G, Clerici M, Padovan L, Chantarangkul V, Scalambrino E, Peyvandi F. Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. J Thromb Thrombolysis. 2019;48:52-60 (IF 2,941).

168. Arcudi S, Ferrari B, Pontiggia S, Tufano A, Artoni A, Mancini I, Peyvandi F. Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. J Thromb Haemost. 2019;17:492-498 (IF 4,662).

169. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019;380:335-346 (IF 70,670).

170. Tripodi A, Chantarangkul V, Clerici M, Bader R, Anzoletti MB, Peyvandi F, Santagostino EM; PredicTGA Collaborators. Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. Thromb Res. 2019;174:84-87 (IF 3,266).

171. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2019;133:415-424 (IF 16,562).

172. Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica. 2019;104:1268-1276 (IF 7,570).

173. Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019;25:33-44 (IF 3.590).

174. Stufano F, Baronciani L, Biguzzi E, Cozzi G, Colpani P, Chisini M, Peyvandi F. Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus. Haemophilia. 2019;25:e30-e32 (letter IF 3,590:5= 0,718).

175. Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost. 2019;17:52-62 (IF 4,662).

176. Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F. Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. Clin Chem. 2019;65:254-262 (IF 6,891).

177. Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome. Semin Thromb Hemost. 2019;45:36-42 (IF 3,401).

178. Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM. Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". Blood Transfus. 2019;17:86 (letter IF 3,352:5=0,670).

2018

179. Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, Peyvandi F, Tripodi A. Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem(R) device. Thromb Res. 2018;172:139-141 (IF 2.779).

180. Artoni A, Bassotti A, Abbattista M, Marinelli B, Lecchi A, Gianniello F, Clerici M, Bucciarelli P, La Marca S, Peyvandi F, Martinelli I. Hemostatic abnormalities in patients with Ehlers-Danlos syndrome. J Thromb Haemost. 2018;16: 2524-2431 (IF 4,899).

181. Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thromb Haemost. 2018;118:1729-1742 (IF 4,952)

182. Mannucci PM, Nobili A, Pasina L; REPOSI Collaborators (REPOSI is the acronym of REgistro POliterapie SIMI, Societa Italiana di Medicina Interna) (Peyvandi F). Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med. 2018;13:1191-1200 (IF 2.453)

183. de Haan HG, van Hylckama Vlieg A, Lotta LA, Gorski MM, Bucciarelli P, Martinelli I; INVENT consortium, Baglin TP, Peyvandi F, Rosendaal FR. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes. J Thromb Haemost. 2018;16: 2432-2441 (IF 4,899)

184. Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdre L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A. Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. Haemophilia. 2018;24:726-732. (IF 2,768)

185. Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, Lopez JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Res Pract Thromb Haemost. 2018;2:407-428.

186. Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2018;2:220-227.

187. Pagliari MT, Baronciani L, Stufano F, Colpani P, Siboni SM, Peyvandi F. Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation. Haemophilia. 2018;24:e263-e266. (IF 2,768)

188. Gorski MM, de Haan HG, Mancini I, Lotta LA, Bucciarelli P, Passamonti SM, Cairo A, Pappalardo E, van Hylckama Vlieg A, Martinelli I, Rosendaal FR, Peyvandi F. Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. Thromb Res. 2018;169:76-81. (IF 2.779)

189. Tripodi A, Braham S, Scimeca B, Moia M, Peyvandi F. How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Pol Arch Intern Med. 2018;128:379-385 (IF2,658)

190. Szederjesi A, Baronciani L, Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Varkonyi A, Patzke J, Bodo I. An international collaborative study by expert centres to compare results from different von Willebrand factor Glycoprotein Ib binding activity assays. J Thromb Haemost. 2018 Jun 13. doi: 10.1111/jth.14206. [Epub ahead of print] (IF 4,899)

191. Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. Thromb Res. 2018;168:20-27. (IF2,779)

192. Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM. Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey. Haemophilia. 2018;24:e266-e268. (IF 2,768)

193. Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM; SIM-AF Collaborators (Peyvandi F). Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation. Br J Clin Pharmacol. 2018;84:2010-2019. (IF 3.838)

194. Giangrande PLF, Hermans C, O'Mahony B, de Kleijn P, Bedford M, Batorova A, Blatny J, Jansone K; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD) (Peyvandi F). European principles of inhibitor management in patients with haemophilia.Orphanet J Rare Dis. 2018;13:66 (IF 3.607)

195. Al-Khabori M, Pathare A, Menegatti M, Peyvandi F. Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss. J Thromb Haemost. 2018;16:1052-1054 (IF 4,899)

196. Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabba C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M. Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. Eur J Intern Med. 2018;52:e12-e14. (IF 3,282)

197. Bulato C, Novembrino C, Anzoletti MB, Spiezia L, Gavasso S, Berbenni C, Tagariello G, Farina C, Nardini I, Campello E, Peyvandi F, Simioni P. "In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. Haemophilia. 2018;24:648-56. (IF 2,768)

198. Paciullo F, Proietti M, Bianconi V, Nobili A, Pirro M, Mannucci PM, Lip GYH, Lupattelli G; REPOSI Investigators (Peyvandi F). Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs Aging. 2018;35:365-373. (IF 2.381)

199. Depetri F, Cugno M, Graziadei G, Di Pierro E, Granata F, Peyvandi F, Cappellini MD. An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia. Intern Emerg Med. 2018;13:1233-1238 (IF 2,453)

200. Pierce GF, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M, van den Berg HM. First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia. 2018;24:229-235. (IF 2,768)

201. Martinelli I, Abbattista M, Bucciarelli P, Tripodi A, Artoni A, Gianniello F, Novembrino C, Peyvandi F. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018l;103:e315-e317 (IF 9,090)

202. Mariani S, Trisolini SM, Capria S, Moleti ML, Chisini M, Ferrazza G, Bafti MS, Limongiello MA, Miulli E, Peyvandi F, Foa R, Testi AM. Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. Haematologica. 2018;103:e138-e140 (IF 9,090)

203. Spena S, Garagiola I, Cannavo A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET Study Group. Prediction of Factor VIII inhibitor development in the SIPPET cohort by mutational analysis and Factor VIII antigen measurement. J Thromb Haemost. 2018;16:778-790 (IF 4,899)

204. Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Cortelezzi A Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia. Br J Haematol. 2018;183:825-828 (IF 5,128)

205. Biguzzi E, Siboni SM, Peyvandi F. Acquired Von Willebrand syndrome and response to desmopressin. Haemophilia. 2018;24:e25-e28. (IF 2,768)

206. Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.J Thromb Haemost. 2018;16:253-261. (IF 4,899)

207. Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion. 2018;58:413-422 (IF 3,423)

208. Rossio R, Arcudi S, Peyvandi F, Piconi S. Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review.Int J Clin Pharmacol Ther. 2018;56:86-89. (IF 1,11)

209. Rimoldi V, Paraboschi EM, Menegatti M, Peyvandi F, Salomon O, Duga S, Asselta R. Molecular investigation of 41 patients affected by coagulation factor XI deficiency. Haemophilia

2018;24:e50-e55. (letter, IF 2,768:5=0,5536)

210. Donadon I, McVey JH, Garagiola I, Branchini A, Mortarino M, Peyvandi F, Bernardi F, Pinotti M. Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis/activity. Haematologica. 2018;103:344-350 (IF 9,090)

211. Stufano F, Baronciani L, Mane-Padros D, Cozzi G, Faraudo S, Peyvandi F. A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method. Haemophilia. 2018;24:156-161. (IF 2,768)

212. Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E, Peyvandi F, Martinelli I. Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. Clin Appl Thromb Hemost. 2018;24:808-814 (IF 1,852)

213. Peyvandi F, Cannavo A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018;16:39-43. (IF 4,899)

214. Fasulo MR, Biguzzi E, Abbattista M, Stufano F, Pagliari MT, Mancini I, Gorski MM, Cannavo A, Corgiolu M, Peyvandi F, Rosendaal FR. The ISTH Bleeding Assessment Tool and the risk of future bleeding. J Thromb Haemost. 2018;16:125-130. (IF 4,899)

215. Karimi M, Peyvandi F, Naderi M, Shapiro A. Factor XIII deficiency diagnosis: Challenges and tools. Int J Lab Hematol. 2018;40:3-11. (Review. IF 1,919)

216. Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G. Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia. 2018;24:57-62. (IF 2,768)

217. Peyvandi F. Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report. Blood Transfus. 2018;16:326-328 (editorial: IF 2,138)

218. Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM. High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfus. 2018;16:215-220 (IF 2,138)

219. Riva S, Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM. Polypharmacy in older adults with severe haemophilia. Haemophilia. 2018;24:e1-e3. (IF 2,768)

2017

220. Menegatti M, Palla R, Bucciarelli P, Peyvandi F. Minimal factor XIII activity level to prevent major spontaneous bleeds: reply. J Thromb Haemost. 2017;15:2280-2282. (letter, IF 5,287:5=1.0574)

221. Mannucci PM, Peyvandi F, Federici AB, Ciavarella N. 9th BIC International Conference: Rome (Italy), 15-17 September 2017. Blood Transfus. 2017 Sep 12;15(Supplement no. 3):s475-s518. (IF 1,607)

222. Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017;130:1757-1759. (IF 13,164)

223. Peyvandi F, Makris M, Collins P, Lillicrap D, Pipe SW, Iorio A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2017;15:1878-1881. (IF 5,287)

224. Jennings I, Kitchen S, Menegatti M, Palla R, Walker I, Peyvandi F, Makris M.Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories. Int J Lab Hematol. 2017;39:653-662. (IF 2,030)

225. Ardoino I, Rossio R, Di Blanca D, Nobili A, Pasina L, Mannucci PM, Peyvandi F, Franchi C; REPOSI Investigators. Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people. Br J Clin Pharmacol. 2017;83:2528-2540. (IF 3,493)

226. Menegatti M, Palla R, Boscarino M, Bucciarelli P, Muszbek L, Katona E, Makris M, Peyvandi F; PRO-RBDD study group.Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost. 2017; 15:1728-1736. (IF 5,287)

227. Asselta R, Paraboschi EM, Rimoldi V, Menegatti M, Peyvandi F, Salomon O, Duga S. Exploring the global landscape of genetic variation in coagulation factor XI deficiency. Blood. 2017;130:e1-e6. (IF 13,164)

228. Cugno M, Mancuso ME, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, Peyvandi F, Mannucci PM. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis. Haemophilia. 2017;23:e348-53. (IF 3,569)

229. Hu Z, Liu Y, Huarng MC, Menegatti M, Reyon D, Rost MS, Norris ZG, Richter CE, Stapleton AN, Chi NC, Peyvandi F, Joung JK, Shavit JA. Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway. Blood. 2017;130:666-676. (IF 13,164)

230. Martinelli I, Abbattista M, Somigliana E, Gianniello F, Peyvandi F. Pregnancy outcome after a first episode of cerebral vein thrombosis: reply. J Thromb Haemost. 2017;15:1526. (letter: IF 5,287:5=1,057)

231. Peyvandi F, Scully M, Kremer Hovinga JA, Knobl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15:1448-1452. (IF 5,287)

232. Mannucci PM, Peyvandi F, Rosendaal FR. Reply to the letter by Iorio. Haemophilia. 2017;23:e248-249. (letter: IF 3,569:5=0,714)

233. Jennings I, Kitchen S, Menegatti M, Palla R, Walker I, Makris M, Peyvandi F. Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. Int J Lab Hematol. 2017;39:350-358. (IF 2,030)

234. Giangrande PL, Peyvandi F, O'Mahony B, Behr-Gross ME, Hilger A, Schramm W, Mannucci PM. Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2017;23:370-375. (IF 3,569)

235. Peyvandi F, Mannucci PM, Palla R, Rosendaal FR. SIPPET: methodology, analysis and generalizability. Haemophilia. 2017;23:353-361. (review, IF 3,569)

236. Bertolotti M, Franchi C, Rocchi MB, Miceli A, Libbra MV, Nobili A, Lancellotti G, Carulli L, Mussi C; REPOSI Investigators. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Societa Italiana di Medicina Interna) Study. Drugs Aging. 2017;34:311-319. (IF 2,769)

237. Messori A, Peyvandi F, Mengato D, Mannucci PM. Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies. Haemophilia. 2017;23(2):e87-e92. (IF 3,569)

238. Baronciani L, Goodeve A, Peyvandi F. Molecular diagnosis of von Willebrand disease. Haemophilia. 2017,23:188-197. (review IF 3,569)

239. Tripodi A, D'Ambrosio R, Padovan L, Tosetti G, Aghemo A, Primignani M, Chantarangkul V, Peyvandi F, Colombo M. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. Liver Int. 2017;37:1295-1303. (IF 4,116)

240. Cannavo A, Valsecchi C, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, Peyvandi F. Non-neutralizing antibodies against factor VIII and risk of inhibitor development in patients with severe hemophilia A. Blood. 2017;129:1245-1250. (IF 13,164)

241. Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM; Wonders Study Investigators. Efficacy and safety of a VWF/FVIII concentrate (wilate(R)) in inherited von Willebrand disease patients undergoing surgical procedures. Haemophilia. 2017;23:264-272. (IF 3,569)

242. Peyvandi F, Makris M. Inhibitor development in haemophilia. Haemophilia. 2017;23 Suppl 1:3. (IF 3,569)

243. Peyvandi F, Ettingshausen CE, Goudemand J, Jimenez-Yuste V, Santagostino E, Makris M. New findings on inhibitor development: from registries to clinical studies. Haemophilia. 2017;23 Suppl 1:4-13. Review. (IF 3,569)

244. Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CR, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F. Summary report of the First International Conference on inhibitors in haemophilia A. Blood Transfus. 2017;15:568-576 (IF 1,607)

245. Mancini I, Ferrari B, Valsecchi C, Pontiggia S, Fornili M, Biganzoli E, Peyvandi F; Italian Group of TTP Investigators. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. Eur J Intern Med. 2017;39:79-83 (IF 2,960)

246. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15:312-322. (IF 5,287)

247. Tripodi A, Ammollo CT, Semeraro F, Colucci M, Malchiodi E, Verrua E, Ferrante E, Arnaldi G, Trementino L, Padovan L, Chantarangkul V, Peyvandi F, Mantovani G. Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine. 2017;56:298-307.(IF 3,131)

2016

248. Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F, Jalali A, Davarpasand T, Akhondzadh S, Shahmansouri N, Lotfi-Tokaldany M, Amiri Abchouyeh M, Ayatollahzade Isfahani F, Rosendaal F. Factors Associated with Depressive Symptoms in Young Adults with Coronary Artery Disease: Tehran Heart Center's Premature Coronary Atherosclerosis Cohort (THC-PAC) Study.Iran J Psychiatry. 2016;11:214-223. (IF -)

249. Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program. 2016;2016:663-669. (IF 2,016)

250. Palla R, Siboni SM, Menegatti M, Musallam KM, Peyvandi F; European Network of Rare Bleeding Disorders (EN-RBD) group. Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thromb Res. 2016;148:128-134. (IF 2,650)

251. Pagliari MT, Lotta LA, de Haan HG, Valsecchi C, Casoli G, Pontiggia S, Martinelli I, Passamonti SM, Rosendaal FR, Peyvandi F. Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. PLoS One. 2016;11:e0165665. (IF 2,806)

252. Pagliari MT, Baronciani L, Stufano F, Garcia-Oya I, Cozzi G, Franchi F, Peyvandi F. von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients. Haemophilia. 2016;22:e502-e511. (IF 3,569)

253. Mancini I, Ricano-Ponce I, Pappalardo E, Cairo A, Gorski MM, Casoli G, Ferrari B, Alberti M, Mikovic D, Noris M, Wijmenga C, Peyvandi F; Italian Group of TTP Investigators. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2016;14:2356-2367. (IF 5,287)

254. Peyvandi F, Garagiola I, Biguzzi E. Advances in treatment of bleeding disorders. J Thromb Haemost. 2016;14:2095-2106.(IF 5,287)

255. Sharief LA, Lawrie AS, Mackie IJ, Halimeh S, Kappert G, Smith C, Peyvandi F, Kadir RA. Plasma factor XIII level variations during menstrual cycle. Blood Coagul Fibrinolysis. 2016;27:786-790. (IF 1,367)

256. Underwood M, Peyvandi F, Garagiola I, Machin S, Mackie I. Degradation of two novel congenital TTP ADAMTS13 mutants by the cell proteasome prevents ADAMTS13 secretion. Thromb Res. 2016;147:16-23. (IF 2,650)

257. Martinelli I, Passamonti SM, Maino A, Abbattista M, Bucciarelli P, Somigliana E, Artoni A, Gianniello F, Peyvandi F. Pregnancy outcome after a first episode of cerebral vein thrombosis. J Thromb Haemost. 2016,14:2386-2393. (IF 5,287)

258. Goudemand J, Peyvandi F, Lacroix-Desmazes S. Key insights to understand the immunogenicity of FVIII products. Thromb Haemost. 2016;116 Suppl 1:S2-9. (IF 5,627)

259. Iorio A, Barbara AM, Bernardi F, Lillicrap D, Makris M, Peyvandi F, Rosendaal F; Subcommittee on Factor VIII, Factor IX & Rare Coagulation Disorder. Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14:1668-72. (IF 5,287)

260. Tripodi A, Primignani M, Braham S, Chantarangkul V, Clerici M, Moia M, Peyvandi F. Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. Dig Liver Dis. 2016;48:1208-13. (IF 3,061)

261. Peyvandi F, Hayward CP. Genomic approaches to bleeding disorders. Haemophilia. 2016 Jul;22 Suppl 5:42-5. (IF 3,569)

262. Peyvandi F, Callewaert F. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016;374:2497-8. (letter: IF 72,406:5=14,481).

263. Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F, Jalali A, Davarpasand T, Akhondzadeh S, Shahmansouri N, Boroumand MA, Lotfi-Tokaldany M, Amiri Abchouyeh M, Ayatollahzade Isfahani F, Rosendaal F. Factors Associated with Anxiety in Premature Coronary Artery Disease Patients: THC-PAC Study. Acta Med Iran. 2016;54:261-269. (IF -)

264. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak

DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016;374:2054-64. (IF 72,406).

265. Mancuso ME, Chantarangkul V, Clerici M, Fasulo MR, Padovan L, Scalambrino E, Peyvandi F, Tripodi A, Santagostino E. Low thrombin generation during major orthopaedic surgery fails to predict the bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia. 2016;22:e292-300. (IF 3,569)

266. Austin SK, Kavakli K, Norton M, Peyvandi F, Shapiro A; FX Investigators Group. Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency. Haemophilia. 2016;22:419-25. (IF 3,569)

267. Mancuso ME, Chantarangkul V, Clerici M, Fasulo MR, Padovan L, Scalambrino E, Peyvandi F, Tripodi A, Santagostino E. The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. Haemophilia. 2016;22:e286-91. (IF 3,569)

268. Colucci M, Incampo F, Cannavo A, Menegatti M, Siboni SM, Zaccaria F, Semeraro N, Peyvandi F. Reduced fibrinolytic resistance in Patients with FXI deficiency. Evidence of a thrombin-independent impairment of the TAFI pathway. J Thromb Haemost. 2016;14:1603-14. (IF 5,287)

269. Garagiola I, Seregni S, Mortarino M, Mancuso ME, Fasulo MR, Notarangelo LD, Peyvandi F. A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect. Mol Genet Genomic Med. 2016;4:152-9. eCollection 2016 Mar. (IF -)

270. Maino A, Siegerink B, Algra A, Martinelli I, Peyvandi F, Rosendaal FR. Pregnancy loss and risk of ischaemic stroke and myocardial infarction. Br J Haematol. 2016;174:302-9. (IF 5,670)

271. Gorski MM, Blighe K, Lotta LA, Pappalardo E, Garagiola I, Mancini I, Mancuso ME, Fasulo MR, Santagostino E, Peyvandi F. Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients. Blood. 2016;127:2924-33. (IF 13,164)

272. Martinelli I, Maino A, Abbattista M, Bucciarelli P, Passamonti SM, Artoni A, Gianniello F, Peyvandi F. Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thromb Res. 2016;141:153-7. (IF 2,650)

273. Gorski MM, Lotta LA, Pappalardo E, de Haan HG, Passamonti SM, van Hylckama Vlieg A, Martinelli I, Peyvandi F. Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis. PLoS One. 2016 Mar 16;11(3):e0151347. doi: 10.1371/journal.pone.0151347. eCollection 2016. (IF 2,806)

274. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016pii:S0140-6736(15)01123-X. (IF 47,831)

275. Rubattu S, Di Castro S, Schulz H, Geurts AM, Cotugno M, Bianchi F, Maatz H, Hummel O, Falak S, Stanzione R, Marchitti S, Scarpino S, Giusti B, Kura A, Gensini GF, Peyvandi F, Mannucci PM, Rasura M, Sciarretta S, Dwinell MR, Hubner N, Volpe M. Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. J Am Heart Assoc. 2016 Feb 17;5(2). pii: e002701. doi: 10.1161/JAHA.115.002701. (IF 5,117)

276. Peyvandi F, Scully M, J. Kremer Hovinga A, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Taleghani MM, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, on behalf of all TITAN investigators. Phase II study of caplacizumab for the treatment of acquired TTP. N Engl J Med 2016;374:511-22 (IF 72,406)

277. Siboni SM, Biguzzi E, Caiani V, Mistretta C, Bucciarelli P, Peyvandi F. Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease. Haemophilia. 2016;22:564-9. (IF 3,569)

278. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Dohner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016;101:115-208. (IF 7,702)

279. Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM; REPOSI Investigators. Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People. Drugs Aging. 2016;33:53-61. (IF 2,769)

280. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14:248-61. (IF 5,287)

281. Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R , Piras R, Cugno M, Noris M. A case report of thrombotic microangiopathy without renal involvement carrying two novel mutations in complement-regulator genes. J Thromb Haemost. 2016;14:340-5. doi: 10.1111/jth.13210. (IF 5,287)

282. Maino A, Siegerink B, Algra A, Peyvandi F, Rosendaal FR. Recurrence and Mortality in Young Women With Myocardial Infarction or Ischemic Stroke: Long-term Follow-up of the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study. JAMA Intern Med. 2016;176:134-6. (IF 16,538)

283. Franchini M, Di Perna C, Santoro C, Castaman G, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S, Coppola A, Santoro R, Napolitano M, Ranalli P, Tagliaferri A; Italian Association of Haemophilia Centres. Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Semin Thromb Hemost. 2016;42:36-41. (IF 3,629)

284. Tripodi A, Martinelli I, Chantarangkul V, Clerici M, Artoni A, Passamonti S, Peyvandi F. Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. Int J Hematol. 2016;103:165-72. (IF 1,610)

285. Lancellotti S, Peyvandi F, Pagliari M, Cairo A, Abdel-Azeim S, Edrisse Chermak E, Lazzareschi I, Mastrangelo S, Cavallo L, Oliva R, De Cristofaro R. The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study. Thromb Haemost. 2016;115:51-62. (IF 5,627)

286. Fischer K, Iorio A, Hollingsworth R, Makris M; all EUHASS collaborators. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia. 2016;22:e36-8. (IF 3,569)

287. Ferrari B, Rossio R, Peyvandi F. Back pain: An old cause in a young adult. Eur J Intern Med. 2016 Mar;28:e1-2 (letter: IF 2,960:5=0,592)

2015

288. van den Berg HM, Peyvandi F. Assessment of Clotting Factor Concentrates-Pivotal Studies and Long-Term Requirements. Semin Thromb Hemost. 2015;41:855-9 (IF 3.505)

289. Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, Noris M. ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clin J Am Soc Nephro. 2015;10:2002-12. (IF 4.657)

290. Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS participants. Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost. 2015;114:670-5. (IF 5,255)

291. Maino A, Rosendaal FR, Algra A, Peyvandi F, Siegerink B. Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review. PLoS One. 2015;10:e0133523. (IF 3.057)

292. Epcacan S, Menegatti M, Akbayram S, Cairo A, Peyvandi F, Oner AF. Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency. Eur J Clin Invest. 2015;45:1087-91. (IF 2.687)

293. Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination. J Thromb Haemost. 2015;13:1806-14. (IF 5.565)

294. Franchini M, Castaman G, Coppola A, Santoro C, Zanon E, Di Minno G, Morfini M, Santagostino E, Rocino A; AICE Working Group. Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus. 2015 Jul;13:498-513. (IF 1.514)

295. Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F, Jalali A, Davarpasand T, Shahmansouri N, Lotfi-Tokaldany M, Abchouyeh MA, Isfahani FA, Rosendaal F. Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study. J Tehran Heart Cent. 2015;10:34-42. (IF -)

296. Maino A, Siegerink B, Lotta LA, Crawley JT, le Cessie S, Leebeek FW, Lane DA, Lowe GD, Peyvandi F, Rosendaal FR. Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis. J Thromb Haemost. 2015;13:1396-404. (IF 5.565)

297. Mannucci PM, Peyvandi F. Introduction and overview. Blood Rev. 2015 Jun;29 Suppl 1:S1-3. (IF 6.627)

298. Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D'Antiga L, PerisicVN, Maggiore G, Caccia S, Duga S. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen -module. J Thromb Haemost. 2015;13:1459-67. (IF 5.565)

299. Asselta R, Robusto M, Plate M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res. 2015;136:168-74. (IF 2.320)

300. Siboni SM, Biguzzi E, Mistretta C, Garagiola I, Peyvandi F. Long-term prophylaxis in severe factor VII deficiency. Haemophilia. 2015;21:812-9. (IF 2.673)

301. Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F, Biganzoli EM, Nobili A, Mannucci PM; REPOSI Investigators. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26:330-7. (IF 2.591)

302. Tripodi A, Padovan L, Chantarangkul V, Scalambrino E, Testa S, Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res. 2015;135:1186-90. (IF 2.320)

303. Rossio R, Conalbi V, Castagna V, Recalcati S, Torri A, Coen M, Cassulini LR, Peyvandi F. Mediterranean spotted fever and hearing impairment: a rare complication. Int J Infect Dis. 2015;35:34-6. (IF 2.229)

304. Bodo I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J; von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:1345-50. (review: IF 5.565)

305. Pastorelli L, Dozio E, Pisani LF, Boscolo-Anzoletti M, Vianello E, Munizio N, Spina L, Tontini GE, Peyvandi F, Corsi Romanelli MM, Vecchi M. Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. Gastroenterol Res Pract. 2015; ID: 189341. (IF 1.742)

306. Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study and collaborators. Eur J Intern Med. 2015;26:243-9. (IF 2.591)

307. Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR; The Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Design of Clinical Trials for New Products in Hemophilia: Communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:876-9. (IF 5.565)

308. Hubbard AR, Heath AB, Kremer Hovinga JA; Subcommittee on von Willebrand Factor. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:1151-3. (IF 5.565)

309. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood. 2015;125:2052-61. (review IF 11,841)

310. Peyvandi F, Garagiola I. Treatment of Hemophilia in the Near Future. Semin Thromb Hemost. 2015;41:838-48. (review IF 3.505)

311. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlov J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Bottcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, Doney AS, Eklund N, Estrada K, Eury E, Folkersen L, Fraser RM, Garcia ME, Geller F, Giedraitis V, Gigante B, Go AS, Golay A, Goodall AH, Gordon SD, Gorski M, Grabe HJ, Grallert H, Grammer TB, Grassler J, Gronberg H, Groves CJ, Gusto G, Haessler J, Hall P, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q,

Hengstenberg C, Holmen O, Hottenga JJ, James AL, Jeff JM, Johansson A, Jolley J, Juliusdottir T, Kinnunen L, Koenig W, Koskenvuo M, Kratzer W, Laitinen J, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindstrom J, Sin Lo K, Lobbens S, Lorbeer R, Lu Y, Mach F, Magnusson PK, Mahajan A, McArdle WL, McLachlan S, Menni C, Merger S, Mihailov E, Milani L, Moayyeri A, Monda KL, Morken MA, Mulas A, Muller G, Muller-Nurasyid M, Musk AW, Nagaraja R, Nothen MM, Nolte IM, Pilz S, Rayner NW, Renstrom F, Rettig R, Ried JS, Ripke S, Robertson NR, Rose LM, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Scott WR, Seufferlein T, Shi J, Vernon Smith A, Smolonska J, Stanton AV, Steinthorsdottir V, Stirrups K, Stringham HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tan ST, Tayo BO, Thorand B, Thorleifsson G, Tyrer JP, Uh HW, Vandenput L, Verhulst FC, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Warren HR, Waterworth D, Weedon MN, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q; LifeLines Cohort Study, Brennan EP, Choi M, Dastani Z, Drong AW, Eriksson P, Franco-Cereceda A, Gadin JR, Gharavi AG, Goddard ME, Handsaker RE, Huang J, Karpe F, Kathiresan S, Keildson S, Kiryluk K, Kubo M, Lee JY, Liang L, Lifton RP, Ma B, McCarroll SA, McKnight AJ, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Okada Y, Perry JR, Dorajoo R, Reinmaa E, Salem RM, Sandholm N, Scott RA, Stolk L, Takahashi A, Tanaka T, Van't Hooft FM, Vinkhuyzen AA, Westra HJ, Zheng W, Zondervan KT; ADIPOGen Consortium; AGEN-BMI Working Group; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GLGC; ICBP; MAGIC Investigators; MuTHER Consortium; MIGen Consortium; PAGE Consortium; ReproGen Consortium; GENIE Consortium; International Endogene Consortium, Heath AC, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Bovet P, Campbell H, Caulfield MJ, Cesana G, Chakravarti A, Chasman DI, Chines PS, Collins FS, Crawford DC, Cupples LA, Cusi D, Danesh J, de Faire U, den Ruijter HM, Dominiczak AF, Erbel R, Erdmann J, Eriksson JG, Farrall M, Felix SB, Ferrannini E, Ferrieres J, Ford I, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gejman PV, Gieger C, Gottesman O, Gudnason V, Gyllensten U, Hall AS, Harris TB, Hattersley AT, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Homuth G, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Illig T, Jacobs KB, Jarvelin MR, Jockel KH, Johansen B, Jousilahti P, Jukema JW, Jula AM, Kaprio J, Kastelein JJ, Keinanen-Kiukaanniemi SM, Kiemeney LA, Knekt P, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, McKenzie CA, McKnight B, Moll FL, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Madden PA, Pasterkamp G, Peden JF, Peters A, Postma DS, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Rioux JD, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schunkert H, Schwarz PE, Sever P, Shuldiner AR, Sinisalo J, Stolk RP, Strauch K, Tonjes A, Tregouet DA, Tremblay A, Tremoli E, Virtamo J, Vohl MC, Volker U, Waeber G, Willemsen G, Witteman JC, Zillikens MC, Adair LS, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bornstein SR, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hui J, Hunter DJ, Hveem K, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, Marz W, Melbye M, Metspalu A, Moebus S, Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sattar N, Schadt EE, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Walker M, Wallaschofski H, Wareham NJ, Watkins H, Weir DR, Wichmann HE, Wilson JF, Zanen P, Borecki IB, Deloukas P, Fox CS, Heid IM, O'Connell JR, Strachan DP, Stefansson K, van Duijn CM, Abecasis GR, Franke L, Frayling TM, McCarthy MI, Visscher PM, Scherag A, Willer CJ, Boehnke M, Mohlke KL, Lindgren CM, Beckmann JS, Barroso I, North KE, Ingelsson E, Hirschhorn JN, Loos RJ, Speliotes EK. Genetic studies of body mass index yield new insights for obesity biology and collaborators. Nature. 2015;518:197-206. (IF 38.138)

312. Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; on behalf of the EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015;113:968-75. (IF 5,255)

313. Berger K, Schopohl D, Hilger A, Behr Gross ME, Giangrande P, Peyvandi F, Seitz R, Schramm W. Research in haemophilia B - approaching the request for high evidence levels in a rare disease. Haemophilia. 2015;21:4-20. (IF 2.673)

314. Franchi C, Salerno F, Conca A, Djade CD, Tettamanti M, Pasina L, Corrao S, Marengoni A, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators. Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. Eur J Intern Med. 2014;25:847-52. (IF 2.891)

315. Biguzzi E, Siboni SM, Ossola MW, Zaina B, Migliorini AC, Peyvandi F. Management of pregnancy in type 2B von Willebrand disease: case report and literature review. Haemophilia. 2015;21:e98-103. (IF2.673)

316. Asselta R, Plate M, Robusto M, Borhany M, Guella I, Solda G, Afrasiabi A, Menegatti M, Shamsi T, Peyvandi F, Duga S. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost. 2015;113:567-76. (IF 5,255)

317. Bucciarelli P, Siboni SM, Stufano F, Biguzzi E, Canciani MT, Baronciani L, Pagliari MT, La Marca S, Mistretta C, Rosendaal FR, Peyvandi F. Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels. J Thromb Haemost. 2015;13:228-36. (IF 5.565)

318. Rossio R, Lotta LA, Pontiggia S, Borsa Ghiringhelli N, Garagiola I, Ardissino G, Mikovic D, Cugno M, Peyvandi F.A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity. Haematologica. 2015;100:e87-9. (letter: IF 6.671=1.334)

319. Tripodi A, Padovan L, Testa S, Legnani C, Chantarangkul V, Scalambrino E, Ludovici S, Bassi L, Peyvandi F. How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. Clin Chem Lab Med. 2015:1;53:265-73. (IF 3.017)

320. Ferrari B, Cairo A, Pontiggia S, Mancini I, Masini L, Peyvandi F. Congenital and acquired ADAMTS13 deficiency: Two mechanisms, one patient. J Clin Apheresis. 2015;30:252-6. (IF 2,432)

2014

321. Ferrari B, Maino A, Lotta LA, Artoni A, Pontiggia S, Trisolini SM, Malato A, Rosendaal FR, Peyvandi F. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. Orphanet J Rare Dis. 2014;9:193. (IF 3.358)

322. Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, Santagostino E, Morfini M; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus. 2014;12:575-98. (IF 2.372)

323. Biguzzi E, Franchi F, Acaia B, Ossola W, Nava U, Paraboschi EM, Asselta R, Peyvandi F. Genetic background and risk of postpartum haemorrhage: results from an Italian cohort of 3219 women. Haemophilia. 2014;20:e377-83. (IF 2.603)

324. Franchi F, Biguzzi E, Stufano F, Siboni SM, Baronciani L, Peyvandi F. A two-step approach (Enzyme-linked immunosorbent assay and confirmation assay) to detect antibodies against von Willebrand factor in patients with Acquired von Willebrand Syndrome.Thromb Res. 2014;134:1316-22. (IF 2.447)

325. Mannucci PM, Nobili A; REPOSI Investigators. Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Intern Emerg Med. 2014;9:723-34. (IF 2.624)

326. Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, Pasina L, Franchi C, Kamal Eldin T, Marengoni A, Salerno F, Marcucci M, Mannucci PM, Nobili A; REPOSI Investigators. Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med. 2014;25:617-23. (IF 2.891)

327. Cugno M, Tedeschi A, Siboni SM, Stufano F, Depetri F, Franchi F, Griffini S, Peyvandi F. Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding. Exp Hematol Oncol. 2014;4:3:15. (IF -)

328. Makris M, Calizzani G, Fischer K, Gatt A, Gilman E, Hollingsworth R, Lambert T, Lassila R, Mannucci PM, Peyvandi F, Windyga J. The European Haemophilia Network (EUHANET). Blood Transfus. 2014;12 Suppl 3:s515-8. (review IF 2.372)

329. Abbonizio F, Giampaolo A, Coppola A; Italian Association of Haemophilia Centres, Arcieri R, Hassan HJ. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia. 2014;20:e243-50. (IF 2.603)

330. O'Mahony B, Peyvandi F, Bok A. Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe ? Haemophilia. 2014;20:455-8 (editorial: IF 2.603:5=0.520)

331. Peyvandi F, Rosendaal FR, O'Mahony B, Mannucci PM. Reply to: The importance and challenge of pediatric trials of hemophilia drugs. Nat Med. 2014 7;20:466 (IF -)

332. Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease: a prospective cohort study of 796 cases. Blood. 2014;123:4037-44. (IF 10.452)

333. Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Joint WFH-ISTH session: issues in clinical trial design. Haemophilia. 2014;20 Suppl 4:137-44. (review IF 2.603)

334. James P, Salomon O, Mikovic D, Peyvandi F. Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia. 2014;20 (Suppl 4):71-5. (review IF 2.603)

335. Mancini I, Valsecchi C, Lotta LA, Deforche L, Pontiggia S, Bajetta M, Palla R, Vanhoorelbeke K, Peyvandi F. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb Haemost. 2014;112:297-303. (IF 4.984)

336. Makris M, Peyvandi F. Assaying FVIII activity: one method is not enough, and never was. Haemophilia. 2014;20:301-3. (editorial: IF 2.603:5=0.520)

337. Tripodi A, Capaccio P, Pignataro L, Chantarangkul V, Menegatti M, Bamonti F, Clerici M, De Giuseppe R, Peyvandi F. Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. Thromb Res. 2014;133:1130-4. (IF 2.447)

338. Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, Bertelli C, Valenti L, Fargion S. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148-54. (IF 11.336)

339. Abdul-Kadir R, McLintock C, Ducloy AS, El-Refaey H, England A, Federici AB, Grotegut CA, Halimeh S, Herman JH, Hofer S, James AH, Kouides PA, Paidas MJ, Peyvandi F, Winikoff R. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion. 2014;54:1756-68. (IF 3.225)

340. Siboni SM, Biguzzi E, Pasta G, Mannucci PM, Mistretta C, Fantini NN, Solimeno LP, Peyvandi F. Management of orthopaedic surgery in rare bleeding disorders. Haemophilia. 2014;20:693-701. (IF 2.603)

341. Franchini M, Coppola A, Rocino A, Zanon E, Morfini M; Italian Association of Haemophilia Centers AICE Working Group, Accorsi A, Aru AB, Biasoli C, Cantori I, Castaman G, Cesaro S, Ciabatta C, De Cristofaro R, Delios G, Di Minno G, D'Inca M, Dragani A, Ettorre CP, Gagliano F, Gamba G, Gandini G, Giordano P, Giuffrida G, Gresele P, Latella C, Luciani M, Margaglione M, Marietta M, Mazzucconi MG, Messina M, Molinari AC, Notarangelo LD, Oliovecchio E, Peyvandi F, Piseddu G, Rossetti G, Rossi V, Santagostino E, Schiavoni M, Schinco P, Serino ML, Tagliaferri A, Testa S. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia. 2014;20:e128-35. (IF 2.603)

342. Boccalandro E, Pasta G, Mannucci PM, Santagostino E, Peyvandi F, Seuser A, Mancuso ME, Solimeno LP. Integrated postural analysis in children with haemophilia. Haemophilia. 2014;20:263-7. (IF 2.603)

343. Peyvandi F, Rosendaal FR, O'Mahony B, Mannuccio Mannucci P. Pediatric requirements in Europe stymie help for hemophilia. Nat Med. 2014;20:117. (opinion: IF 28.223)

344. Menegatti M, Vangone A, Palla R, Milano G, Cavallo L, Oliva R, De Cristofaro R, Peyvandi F. A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking. Thromb Res. 2014;133:481-7. (IF 2.447)

345. Lotta LA, Valsecchi C, Pontiggia S, Mancini I, Cannavo A, Artoni A, Mikovic D, Meloni G, Peyvandi F. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2014;12:329-36. (IF 5,720)

346. Sharief LT, Lawrie AS, Mackie IJ, Smith C, Peyvandi F, Kadir RA. Changes in factor XIII level during pregnancy. Haemophilia. 2014;20:144-148. (IF 2.603)

347. Borhany M, Handrkova H, Cairo A, Schroeder V, Fatima N, Naz A, Amanat S, Shamsi T, Peyvandi F, Kohler HP. Congenital factor XIII deficiency in Pakistan: characterization of seven families and identification of four novel mutations. Haemophilia. 2014;20:568-74. (IF 2.603)

348. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia. 2014;20:147-53. (IF 2.603)

349. Siboni SM, Biguzzi E, Solimeno LP, Pasta G, Mistretta C, Mannucci PM, Peyvandi F. Orthopaedic surgery in patients with von Willebrand disease. Haemophilia. 2014;20:133-40. (IF 2.603)

2013

350. Martinelli I, Bucciarelli P, Artoni A, Fossali EF, Passamonti SM, Tripodi A, Peyvandi F. Anticoagulant treatment with rivaroxaban in severe protein s deficiency. Pediatrics 2013;132:e1435-9. (IF 5.297)

351. Kadir RA, Davies J, Winikoff R, Pollard D, Peyvandi F, Garagiola I, Pabinger I, Federici AB. Pregnancy complications and obstetric care in women with inherited bleeding disorders.

Haemophilia 2013;19 (Suppl 4):1-10. (review IF 2.468)

352. Peyvandi F, Kunicki T, Lillicrap D. Genetic sequence analysis of inherited bleeding diseases. Blood 2013;122:3423-31. (review IF 9.775)

353. Vucelic D, Mikovic D, Rajic Z, Savic N, Budisin Z, Antonijevic NM, Obradovic S, Jevtic D, Palla R, Valsecchio C, Peyvandi F. Diagnostic relevance of ADAMTS13 activity: evaluation of 28 patients with thrombotic thrombocytopenic purpura - hemolytic uremic syndrome clinical diagnosis. Srp Arh Celok Lek. 2013;141:466-74. (IF 0.169)

354. Marcucci M, Nobili A, Tettamanti M, Iorio A, Pasina L, Djade CD, Franchi C, Marengoni A, Salerno F, Corrao S, Violi F, Mannucci PM; REPOSI Investigators. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur J Intern Med. 2013;24:800-6. (IF 2.300)

355. Franchi F, Biguzzi E, Martinelli I, Bucciarelli P, Palmucci C, D'Agostino S, Peyvandi F. Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status.Thromb Res. 2013;132:e152-7. (IF 2.427)

356. Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost. 2013;39:579-84. (review IF 3.693)

357. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost. 2013;11 Suppl 1:84-98. (review IF 5,550)

358. Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, van Heerde WL. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res. 2013;132:256-62. (IF 2.427)

359. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, Gatti L, Mannucci PM, Peyvandi F. Global coagulation in myeloproliferative neoplasms. Ann Hematol. 2013;92:1633-9. (IF 2.396)

360. Scaglione GL, Lancellotti S, Pap M, De Spirito M, Maiorana A, Baronciani L, Pagliari MT, Arcovito A, Di Stasio E, Peyvandi F, De Cristofaro R. The Type 2b P.R1306w Natural Mutation Of Von Willebrand Factor Dramatically Enhances The Multimer Sensitivity To Shear Stress. J Thromb Haemost. 2013;11:1688-98. (IF 5.550)

361. Peyvandi F, Mannucci PM, Valsecchi C, Pontiggia S, Farina C, Retzios AD. ADAMTS13 content in plasma-derived factor VIII/ von willebrand factor concentrates. Am J Hematol. 2013;88:895-8. (IF 3.477)

362. Musallam KM, Rosendaal FR, Zaatari G, Soweid A, Hoballah JJ, Sfeir PM, Zeineldine S, Tamim HM, Richards T, Spahn DR, Lotta LA, Peyvandi F, Jamali FR. Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. JAMA Surg. 2013;148:755-62. (IF -)

363. Musallam KM, Porter JB, Sfeir PM, Tamim HM, Richards T, Lotta LA, Peyvandi F, Jamali FR. Raised haematocrit concentration and the risk of death and vascular complications after major surgery. Br J Surg. 2013;100:1030-6. (IF 5.210)

364. Musallam KM, Jamali FR, Rosendaal FR, Richards T, Spahn DR, Khavandi K, Barakat I, Demoss B, Lotta LA, Peyvandi F, Sfeir PM. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. Anemia. 2013; ID 206829. doi: 10.1155/2013/206829. (IF -)

365. van Geffen M, Mathijssen NC, Holme PA, Laros-van Gorkom BA, van Kraaij MG, Masereeuw R, Peyvandi F, van Heerde WL. Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients. Thromb Res. 2013;132:116-22. (IF 2.427)

366. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, Marengoni A, Salerno F, Corrao S, Mannucci PM; REPOSI Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med. 2013;8:509-20. (IF 2.410)

367. Lotta LA, Tuana G, Yu J, Martinelli I, Wang M, Yu F, Passamonti SM, Pappalardo E, Valsecchi C, Scherer SE, Hale Iv W, Muzny DM, Randi G, Rosendaal FR, Gibbs RA, Peyvandi F. Next-generation sequencing study finds an excess of rare, coding single nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. J Thromb Haemost. 2013;11:1228-39. (IF 5.550)

368. Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98:667-74. (IF 5.868)

369. Pagliari MT, Baronciani L, Garcia Oya I, Solimando M, La Marca S, Cozzi G, Stufano F, Canciani MT, Peyvandi F. A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation

cause exon 26 skipping in four patients with von Willebrand disease (2A/IIE). J Thromb Haemost. 2013;11:1251-9. (IF 5.550)

370. Lotta LA, Maino A, Tuana G, Rossio R, Lecchi A, Artoni A, Peyvandi F. Prevalence of disease and relationships between laboratory phenotype and bleeding severity in platelet primary secretion defects. PloS One. 2013;8:e60396. (IF 3.534)

371. Lotta LA, Wu HM, Musallam KM, Peyvandi F. The emerging concept of residual ADAMTS13 activity in ADAMTS-13-deficient thrombotic thrombocytopenic purpura. Blood Rev. 2013: 27:71-6. (IF 5.451)

372. Zekavat OR, Haghpanah S, Dehghani J, Afrasiabi A, Peyvandi F, Karimi M. Comparison of Thrombin Generation Assay with Conventional Coagulation Tests in Evaluation of Bleeding Risk in Patients With rare Bleeding Disorders. Clin Appl Thromb Hemost. 2013;20:637-644. (IF 1.575)

373. Marengoni A, Nobili A, Pirali C, Tettamanti M, Pasina L, Salerno F, Corrao S, Iorio A, Marcucci M, Franchi C, Mannucci PM; REPOSI Investigators. Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. Gerontology. 2013;59:307-15. (IF 2.681)

374. Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost. 2013; 109:488-96. (IF 5.760)

375. Vucelic D, Rajic Z, Savic N, Mikovic D, Budisin Z, Antonijevic NM, Obradovic S, Jevtic D, Bettoni G, Casoli G, Peyvandi F. Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients. Acta Chir Iugosl. 2013;60:29-38. (IF -)

376. Musallam KM, Khalife M, Sfeir PM, Faraj W, Safadi B, Abi Saad GS, Abiad F, Hallal A, Alwan MB, Peyvandi F, Jamali FR. Postoperative Outcomes After Laparoscopic Compared With Open Splenectomy. Ann Surg. 2013;257:1116-23. (IF 7.188)

377. Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia. 2013;19: 338-42. (IF 2,468)

378. Franchi C, Nobili A, Mari D, Tettamanti M, Djade CD, Pasina L, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM, REPOSI Investigators. Risk factors for hospital readmission of elderly patients. Eur J Intern Med. 2013;24:45-51. (IF 2.300)

379. Lotta LA, Degasperi E, Aghemo A, Ferrari B, Peyvandi F, Colombo M. Treatment of chronic epatitis C with pegylated interferon- in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura. Transfus Med. 2013;23:66-8. (letter: IF 1.308 = 0.262)

380. Garagiola I, Mortarino M, Semprini AE, Peyvandi F. Reproductive care in human immunodeficiency virus serodiscordant couples with haemophilia. Blood Transfus. 2013;11:469-70. (letter: IF 1.901: 5 = 0.380)

381. Rossio R, Ferrari B, Cairo A, Mancini I, Pisapia G, Palazzo G, Peyvandi F. Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpura. Blood Transfus. 2013; 11:241-4. (IF 1.901)

382. Rubattu S, Giusti B, Lotta LA, Peyvandi F, Cotugno M, Stanzione R, Marchitti S, Palombella AM, Di Castro S, Rasura M, Mannucci PM, Volpe M. Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. Eur J Intern Med. 2013;24:80-2. (IF 2.300)

383. Lotta LA, Wu HM, Cairo A, Bentivoglio G, Peyvandi F. Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2013;50:59-60. (letter: IF 2.331:5 = 0.466)

2012

384. Peyvandi F. Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130 Suppl 2:S7-11. (IF3.133)

385. Rosendaal FR, Peyvandi F. Pediatric stroke and ADAMTS genes. Blood. 2012;120:5097-8. (commentary: IF 9.060:5=1.812)

386. Lotta LA, Martinelli I, Peyvandi F. Prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012;367:1069. (letter: IF 51,658:5 = 10.332)

387. Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; for the Project on Consensus Definitions in Rare Bleeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012;10:1938-43. (IF 6,081)

388. Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia. 2012;18 Suppl 4:148-53. (IF 3.170)

389. Lucas G, Lluis-Ganella C, Subirana I, Musameh MD, Gonzalez JR, Nelson CP, Senti M; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Schwartz SM, Siscovick D, O'Donnell CJ, Melander O, Salomaa V, Purcell S, Altshuler D, Samani NJ, Kathiresan S, Elosua R. Hypothesis-based analysis of gene-gene interactions and risk of myocardial infarction. PLoS One. 2012;7:e41730. (IF: 3.730)

390. Stahl EA, Wegmann D, Trynka G, Gutierrez-Achury J, Do R, Voight BF, Kraft P, Chen R, Kallberg HJ, Kurreeman FA; Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction Genetics Consortium, Kathiresan S, Wijmenga C, Gregersen PK, Alfredsson L, Siminovitch KA, Worthington J, de Bakker PI, Raychaudhuri S, Plenge RM. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet. 2012;44:483-9. (IF 35.209)

391. Solimando M, Baronciani L, La Marca S, Cozzi G, Asselta R, Canciani MT, Federici AB, Peyvandi F. Molecular characterization, recombinant protein expression, and mRNA analysis of type 3 von Willebrand disease: Studies of an Italian cohort of 10 patients. Am J Hematol. 2012;87:870-4. (IF 4.138)

392. Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta LA, Trisolini SM, Mancini I, Musallam KM, Rosendaal FR, Peyvandi F. ADAMTS13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012;10:1556-65. (IF 6,081)

393. Bafunno V, Santacroce R, Chetta M, Peyvandi F, Sessa F, Chinni E, Longo V, Margaglione M. Polymorphic miRNA-mediated gene contribution to inhibitor development in haemophilia A. Haemophilia. 2012;18:1003-7. (IF 3.170)

394. Peyvandi F, Klamroth R, Carcao M, Federici AB, DI Minno G, Jimenez-Yuste V, Rodriguez Merchan EC. Management of bleeding disorders in adults. Haemophilia. 2012;18 (Suppl 2):24-36. (review: IF 3.170)

395. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ; on behalf of British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323-35. (IF 4.942)

396. Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJ, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25:2322-5. (IF 1.518)

397. Peyvandi F. Willebrand disease. Haemophilia. 2012;18 (Suppl 2):1. (editorial: IF 3.170:5=0.634)

398. Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, Peyvandi F. Residual plasmatic activity of ADAMTS13 correlates with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120:440-8. (IF 9.060)

399. Peyvandi F, Biguzzi E, Franchi F, Bucciarelli P, Acaia B, Zaina B, Musallam KM. Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. J Thromb Haemost. 2012;10:1451-3. (letter: IF 6.081: 5 = 1.216)

400. Mancini I, Valsecchi C, Palla R, Lotta LA, Peyvandi F. Measurement of anti-ADAMTS13 neutralising autoantibodies: a comparison between CBA and FRET assays. J Thromb Haemost. 2012;10:1439-42. (letter: IF 6.081: 5 = 1.216)

401. Cataland SR, Peyvandi F, Mannucci PM, Lammle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87:430-2. (letter IF 4.138:5 = 0.828)

402. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolnicar M, Kitanovski L, Mikovic D, Musallam KM, Rosendaal FR; ON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD) GROUP. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10:615-621. (IF 6.081)

403. Stufano F, La Marca S, Pontiggia S, Musallam KM, Peyvandi F. Von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost.

2012;10:728-30. (letter: IF 6.081: 5 = 1.216)

404. Lotta LA, Mancini I, Tuana G, Musallam KM, Peyvandi F. Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2012;34:416-8. (IF 1.985)

405. Karimi M, Vafafar A, Haghpanah S, Payandeh M, Eshghi P, Hoofar H, Afrasiabi A, Gerdabi J, Ardeshiri R, Menegatti M, Peyvandi F. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia. 2012;18:211-5. (IF 3.170)

406. Lotta LA, Wang M, Yu J, Martinelli I, Yu F, Passamonti SM, Consonni D, Pappalardo E, Menegatti M, Scherer SE, Lewis LL, Akbar H, Wu Y, Bainbridge MN, Muzny DM, Mannucci PM, Gibbs RA, Peyvandi F. Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes. BMC Med Genomics. 2012;5:7. (IF 3.466)

407. Mannucci PM, Gringeri A, Santagostino E, Peyvandi F. Factor VIII inhibitor and source of replacement therapy. Blood Transfus. 2012;10:112-3. (letter IF 1.858:5 = 0.371)

408. Siboni SM, Zanon E, Sottilotta G, Consonni D, Castaman G, Mikovic D, Biondo F, Tagliaferri A, Iorio A, Mannucci PM, Peyvandi F. Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia. 2012;18:34-8. (IF 3.170)

409. Eshghi P, Cohan N, Lak M, Naderi M, Peyvandi F, Menegatti M, Karimi M. Arg77His and Trp187Arg are the Most Common Mutations Causing FXIII Deficiency in Iran. Clin Appl Thromb Hemost. 2012;18:100-3. (IF 1.016)

410. Paraboschi EM, Kayiran SM, Ozbek N, Gurakan B, Peyvandi F, Guella I, Duga S, Asselta R. Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency. Haemophilia. 2012;18:205-10. (IF 3.170)

2011

411. Shapiro AD, Soucie JM, Peyvandi F, Aschman DJ, Dimichele DM; UDC Rare Bleeding and Clotting Disorders Working Group and the European Network Rare Bleeding Disorders Database. Knowledge and therapeutic gaps a public health problem in the rare coagulation disorders population. Am J Prev Med. 2011;41(Suppl 4):S324-31. (IF 4.044)

412. Peyvandi F, Bidlingmaier C, Garagiola I. Management of pregnancy and delivery in women with inherited bleeding disorders. Semin Fetal Neonatal Med. 2011;16:311-7. (review: IF 3.915)

413. Mariani M, Cairo A, Palla R, Lotta LA, Consonni D, Rovati A, Trisolini S, Peyvandi F. B and T lymphocytes in acquired Thrombotic Thrombocytopenic Purpura during disease remission. Thromb Res. 2011;128:590-2. (letter IF 2.440:5 = 0.488)

414. Mortarino M, Garagiola I, Lotta LA, Siboni SM, Semprini AE, Peyvandi F. Non-invasive tool for foetal sex determination in early gestational age. Haemophilia. 2011;17:952-6. (IF 2.597)

415. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, Rybin D, Petrie JR, Travers ME, Bouatia-Naji N, Dimas AS, Nica A, Wheeler E, Chen H, Voight BF, Taneera J, Kanoni S, Peden JF, Turrini F, Gustafsson S, Zabena C, Almgren P, Barker DJ, Barnes D, Dennison EM, Eriksson JG, Eriksson P, Eury E, Folkersen L, Fox CS, Frayling TM, Goel A, Gu HF, Horikoshi M, Isomaa B, Jackson AU, Jameson KA, Kajantie E, Kerr-Conte J, Kuulasmaa T, Kuusisto J, Loos RJ, Luan J, Makrilakis K, Manning AK, Martinez-Larrad MT, Narisu N, Nastase Mannila M, Ohrvik J, Osmond C, Pascoe L, Payne F, Sayer AA, Sennblad B, Silveira A, Stancakova A, Stirrups K, Swift AJ, Syvanen AC, Tuomi T, van 't Hooft FM, Walker M, Weedon MN, Xie W, Zethelius B; DIAGRAM Consortium; GIANT Consortium; MuTHER Consortium; CARDIoGRAM Consortium; CAD Consortium, Ongen H, Malarstig A, Hopewell JC, Saleheen D, Chambers J, Parish S, Danesh J, Kooner J, Ostenson CG, Lind L, Cooper CC, Serrano-Rios M, Ferrannini E, Forsen TJ, Clarke R, Franzosi MG, Seedorf U, Watkins H, Froguel P, Johnson P, Deloukas P, Collins FS, Laakso M, Dermitzakis ET, Boehnke M, McCarthy MI, Wareham NJ, Groop L, Pattou F, Gloyn AL, Dedoussis GV, Lyssenko V, Meigs JB, Barroso I, Watanabe RM, Ingelsson E, Langenberg C, Hamsten A, Florez JC. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes. 2011;60:2624-34. (IF 8.286)

416. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Lee CA, Martinez-Perez O, McLintock C, Peyvandi F, Philipp C, Wilkinson J, Winikoff R. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158:124-34. (review: IF 1.974)

417. Guella I, Duga S, Ardissino D, Merlini PA, Peyvandi F, Mannucci PM, Asselta R. Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population. Thromb Haemost. 2011;106:655-64. (IF 5.044)

418. Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol. 2011;18:366-72. (review: IF 4.520)

419. Haghpanah S, Sahraiian M, Afrasiabi A, Enayati S, Peyvandi F, Karimi M. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran. Haemophilia. 2011;17:820-1. (letter IF 2.597:5 = 0.519)

420. Lotta LA, Lombardi R, Mariani M, Lancellotti S, De Cristofaro R, Hollestelle MJ, Canciani MT, Mannucci PM, Peyvandi F. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission. J Thromb Haemost. 2011;9:1744-51. (IF 5.731)

421. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost. 2011;9:1687-704. (review: IF 5.731)

422. IBC 50K CAD Consortium. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet. 2011;7:e1002260. (IF 8.694)

423. Hubbard AR, Hamill M, Beeharry M, Bevan SA, Heath AB; SSC sub-committee on von Willebrand factor of ISTH. Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182). J Thromb Haemost. 2011;9:1638-40. (IF 5.731)

424. Lancellotti S, De Filippis V, Pozzi N, Oggianu L, Rutella S, Scaglione GL, Maset F, Peyvandi F, Mannucci PM, De Cristofaro R. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13. J Thromb Haemost. 2011;9:1620-7. (IF 5.731)

425. Ardissino D, Berzuini C, Merlini PA, Mannucci PM, Surti A, Burtt N, Voight B, Tubaro M, Peyvandi F, Spreafico M, Celli P, Lina D, Notarangelo MF, Ferrario M, Fetiveau R, Casari G, Galli M, Ribichini F, Rossi ML, Bernardi F, Marziliano N, Zonzin P, Mauri F, Piazza A, Foco L, Bernardinelli L, Altshuler D, Kathiresan S; Italian Atherosclerosis, Thrombosis and Vascular Biology Investigators. Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol. 2011;58:426-34. (IF 14.156)

426. Mahmoodi M, Peyvandi F, Afrasiabi A, Ghaffarpasand F, Karimi M. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagul Fibrinolysis. 2011;22:396-401. (IF 1.238)

427. Peyvandi F, Garagiola I, Mortarino M. Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. Haemophilia. 2011;17 (Suppl 1):14-7. (IF 2.597)

428. Peyvandi F, Garagiola I, Menegatti M. Gynecological and obstetrical manifestations of inherited bleeding disorders in women. J Thromb Haemost. 2011;9 (Suppl 1):236-45. (review: IF 5.731)

429. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus. 2011;9 (Suppl 2):s3-8. (review: IF 2.099)

430. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I; Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA, Mooser V, Morgan T, Muhleisen TW, Muhlestein JB, Munzel T, Musunuru K, Nahrstaedt J, Nelson CP, Nothen MM, Olivieri O, Patel RS, Patterson CC, Peters A, Peyvandi F, Qu L, Quyyumi AA, Rader DJ, Rallidis LS, Rice C, Rosendaal FR, Rubin D, Salomaa V, Sampietro ML, Sandhu MS, Schadt E, Schafer A, Schillert A, Schreiber S, Schrezenmeir J, Schwartz SM, Siscovick DS, Sivananthan M, Sivapalaratnam S, Smith A, Smith TB, Snoep JD, Soranzo N, Spertus JA, Stark K, Stirrups K, Stoll M, Tang WH, Tennstedt S, Thorgeirsson G, Thorleifsson G, Tomaszewski M, Uitterlinden AG, van Rij AM, Voight BF, Wareham NJ, Wells GA, Wichmann HE, Wild PS, Willenborg C, Witteman JC, Wright BJ, Ye S, Zeller T, Ziegler A, Cambien F, Goodall AH, Cupples LA, Quertermous T, Marz W, Hengstenberg C, Blankenberg S, Ouwehand WH, Hall AS, Deloukas P, Thompson JR, Stefansson K, Roberts R, Thorsteinsdottir U, O'Donnell CJ, McPherson R, Erdmann J; CARDIoGRAM Consortium, Samani NJ. Large-scale association analysis identifies 13

new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-8. (IF 35.532)

431. Lawrie AS, Mackie IJ, Machin SJ, Peyvandi F. Evaluation of an automated platelet-based assay of ristocetin cofactor activity. Haemophilia. 2011;17:252-6. (IF 2.597)

432. De Caterina R, Talmud PJ, Merlini PA, Foco L, Pastorino R, Altshuler D, Mauri F, Peyvandi F, Lina D, Kathiresan S, Bernardinelli L, Ardissino D; Gruppo Italiano Aterosclerosi. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis. 2011;214:397-403. (IF 3.794)

433. Palla R, Valsecchi C, Bajetta M, Spreafico M, De Cristofaro R, Peyvandi F. Evaluation of assay methods to measure plasma ADAMTS13 activity in thrombotic microangiopathies. Thromb Haemost. 2011;105:381-5. (letter IF 5.044:5 = 1.009)

434. Peyvandi F, Menegatti M, Siboni SM. Post-partum hemorrhage in women with rare bleeding disorders. Thromb Res. 2011;127 (Suppl 3):S116-9. (IF 2.440)

435. Lotta LA, Peyvandi F. Addressing the complexity of cardiovascular disease by design. Lancet. 2011;377:356-8. (commentary IF 38.278:5 = 7.656)

436. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, Horne BD, Stewart AF, Assimes TL, Wild PS, Allayee H, Nitschke PL, Patel RS; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium, Martinelli N, Girelli D, Quyyumi AA, Anderson JL, Erdmann J, Hall AS, Schunkert H, Quertermous T, Blankenberg S, Hazen SL, Roberts R, Kathiresan S, Samani NJ, Epstein SE, Rader DJ. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:383-92. (IF 38.278)

2010

437. Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A, Vucelic D, Pizzuti M, Mannucci PM, Peyvandi F. Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol. 2010;151:488-94. (IF 4.942)

438. Peyvandi F, Palla R, Lotta LA. Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95:1444-7 (commentary IF 6.532:5 = 1.306)

439. Lawrie AS, Green L, Mackie IJ, Liesner R, Machin SJ, Peyvandi F. Factor XIII - an under diagnosed deficiency - are we using the right assays? J Thromb Haemost. 2010;8:2478-82. (IF 5.439)

440. Guella I, Asselta R, Ardissino D, Merlini PA, Peyvandi F, Kathiresan S, Mannucci PM, Tubaro M, Duga S. Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res. 2010;51:3342-9. (IF 6.115)

441. Mannucci PM, Asselta R, Duga S, Guella I, Spreafico M, Lotta L, Merlini PA, Peyvandi F, Kathiresan S, Ardissino D. The association of factor V Leiden with myocardial infarction is replicated in 1,880 patients with premature disease. J Thromb Haemost. 2010;8: 2116-21. (IF 5.439)

442. Feys HB, Vandeputte N, Palla R, Peyvandi F, Peerlinck K, Deckmyn H, Lijnen HR, Vanhoorelbeke K. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:2053-62. (IF 5.439)

443. Lawrie AS, Green L, Canciani MT, Mackie IJ, Peyvandi F, Scully MA, Machin SJ. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang. 2010;99:232-8. (IF 3.292)

444. Lotta LA, Giusti B, Saracini C, Vestrini A, Volpe M, Rubattu S, Peyvandi F. No association between chromosome 12p13 single nucleotide polymorphisms and early-onset ischemic stroke. J Thromb Haemost. 2010;8:1858-60. (letter IF 5.439:5 = 1.088)

445. Mannucci PM, Lotta LA, Peyvandi F. Genome-wide association studies in myocardial infarction and coronary artery disease. J Teh Univ Heart Ctr 2010;5:116-21. (IF -)

446. Giusti B, Saracini C, Bolli P, Magi A, Martinelli I, Peyvandi F, Rasura M, Volpe M, Lotta LA, Rubattu S, Mannucci PM, Abbate R. Early-onset ischaemic stroke: analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. Thromb Haemost. 2010;104:231-42. (IF 4.701)

447. Peyvandi F, Hollestelle MJ, Palla R, Merlini PA, Feys HB, Vanhoorelbeke K, Lenting PJ, Mannucci PM. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction. J Thromb Haemost. 2010;8:1653-6. (letter IF 5.439:5 = 1.088)

448. Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:631-40. (review: IF 5.439)

449. Asselta R, Rimoldi V, Guella I, Solda G, De Cristofaro R, Peyvandi F, Duga S. Molecular characterization of in-frame and out-of-frame alternative splicings in coagulation factor XI

pre-mRNA. Blood. 2010;115:2065-72. (IF 10.558)

450. Bafunno V, Santacroce R, Chetta M, D'Andrea G, Pisanelli D, Sessa F, Trotta T, Tagariello G, Peyvandi F, Margaglione M. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia. 2010;16:469-73. (IF 2.364)

451. Lancellotti S, De Filippis V, Pozzi N, Peyvandi F, Palla R, Rocca B, Rutella S, Pitocco D, Mannucci PM, De Cristofaro R. Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med. 2010;48:446-56. (IF 5.707)

452. Baronciani L, Peyvandi F, Punzo M, Lancellotti S, Canciani MT, Federici AB, De Cristofaro R. Relevance of chloride binding to von Willebrand factor in type 2B von Willebrand disease patients. J Thromb Haemost. 2010;8:416-8. (letter IF 5.439:5 = 1.088)

453. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31:11-9. (review: IF 5.956)

2009

454. Peyvandi F, Palla R. Fibrinogen concentrates. Clin Adv Hematol Oncol. 2009;7:788-90. (commentary: IF -)

455. Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res. 2009;124 (Suppl 2):S9-11. (IF 2.406)

456. Guella I, Rimoldi V, Asselta R, Ardissino D, Francolini M, Martinelli N, Girelli D, Peyvandi F, Tubaro M, Merlini PA, Mannucci PM, Duga S. Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease. Circ-Cardiovasc Genet. 2009;2:165-72. (IF 4.043)

457. Girelli D, Martinelli N, Peyvandi F, Olivieri O. Genetic architecture of coronary artery disease in the genome-wide era: implications for the emerging "golden dozen" loci. Semin Thromb Hemost. 2009;35:671-82. (review: IF 3.214)

458. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P; FIBRINOGEN CONCENTRATE STUDY GROUP. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009;7:2064-9. (IF 6.069)

459. Spena S, Asselta R, Caccia S, Rimoldi V, Giacomelli SH, Tagliaferri A, Peyvandi F, Castaman G, Duga S. Analysis of the structural effects of four novel and a previously known mutations causing factor XI deficiency. Thromb Haemost. 2009;102:603-6. (letter IF 4.451:5 = 0.890)

460. Siboni SM, Spreafico M, Calo L, Maino A, Santagostino E, Federici AB, Peyvandi F. Gynaecological and obstetrical problems in women with different bleeding disorders. Haemophilia. 2009;15:1291-9. (IF 2.505)

461. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407-15. (review: IF 3.214)

462. Spreafico M, Peyvandi F. Combined Factor V and Factor VIII Deficiency. Semin Thromb Hemost. 2009;35:390-9. (review: IF 3.214)

463. Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009;35:382-9. (review: IF 3.214)

464. Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost. 2009;35:349-55. (review: IF 3.214)

465. Peyvandi F, Favaloro EJ. Rare bleeding disorders. Semin Thromb Hemost. 2009;35:345-7. (editorial: IF 3.214:5 = 0.643)

466. James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, Kamphuisen PW, Konkle BA, Martinez-Perez O, McLintock C, Peyvandi F, Winikoff R. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009;201:12.e1-8. (IF 3.278)

467. Mannucci PM, Peyvandi F. Autoimmune hemophilia at rescue. Haematologica. 2009;94:459-61. (editorial: IF 6.416:5 = 1.283)

468. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, Batorova A, Lapecorella M, Schved JF, Ingerslev J, Mariani G; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost. 2009;7:774-9 (IF 6.069)

469. Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick

DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, Zeller T, Wild P, Schwarz DF, Tiret L, Perret C, Schreiber S, El Mokhtari NE, Schafer A, Marz W, Renner W, Bugert P, Kluter H, Schrezenmeir J, Rubin D, Ball SG, Balmforth AJ, Wichmann HE, Meitinger T, Fischer M, Meisinger C, Baumert J, Peters A, Ouwehand WH; Italian Atherosclerosis, Thrombosis, and Vascular Biology Working Group; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium; Cardiogenics Consortium, Deloukas P, Thompson JR, Ziegler A, Samani NJ, Schunkert H. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41:280-2. (IF 34.284)

470. Myocardial Infarction Genetics Consortium, Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, Erdmann J, Reilly MP, Rader DJ, Morgan T, Spertus JA, Stoll M, Girelli D, McKeown PP, Patterson CC, Siscovick DS, O'Donnell CJ, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Melander O, Altshuler D, Ardissino D, Merlini PA, Berzuini C, Bernardinelli L, Peyvandi F, Tubaro M, Celli P, Ferrario M, Fetiveau R, Marziliano N, Casari G, Galli M, Ribichini F, Rossi M, Bernardi F, Zonzin P, Piazza A, Mannucci PM, Schwartz SM, Siscovick DS, Yee J, Friedlander Y, Elosua R, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Kathiresan S, Meigs JB, Williams G, Nathan DM, MacRae CA, O'Donnell CJ, Salomaa V, Havulinna AS, Peltonen L, Melander O, Berglund G, Voight BF, Kathiresan S, Hirschhorn JN, Asselta R, Duga S, Spreafico M, Musunuru K, Daly MJ, Purcell S, Voight BF, Purcell S, Nemesh J, Korn JM, McCarroll SA, Schwartz SM, Yee J, Kathiresan S, Lucas G, Subirana I, Elosua R, Surti A, Guiducci C, Gianniny L, Mirel D, Parkin M, Burtt N, Gabriel SB, Samani NJ, Thompson JR, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Hall AS; Wellcome Trust Case Control Consortium, Schunkert H, Erdmann J, Linsel-Nitschke P, Lieb W, Ziegler A, Konig I, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Schunkert H, Samani NJ, Erdmann J, Ouwehand W, Hengstenberg C, Deloukas P, Scholz M, Cambien F, Reilly MP, Li M, Chen Z, Wilensky R, Matthai W, Qasim A, Hakonarson HH, Devaney J, Burnett MS, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Epstein SE, Rader DJ, Scheffold T, Berger K, Stoll M, Huge A, Girelli D, Martinelli N, Olivieri O, Corrocher R, Morgan T, Spertus JA, McKeown P, Patterson CC, Schunkert H, Erdmann E, Linsel-Nitschke P, Lieb W, Ziegler A, Konig IR, Hengstenberg C, Fischer M, Stark K, Grosshennig A, Preuss M, Wichmann HE, Schreiber S, Holm H, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Engert JC, Do R, Xie C, Anand S, Kathiresan S, Ardissino D, Mannucci PM, Siscovick D, O'Donnell CJ, Samani NJ, Melander O, Elosua R, Peltonen L, Salomaa V, Schwartz SM, Altshuler D. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41:334-41. (IF 34.284)

471. Karimi M, Jafari H, Lahsaeizadeh S, Afrasiabi A, Akbari A, Dehbozorgian J, Ardeshiri R, Guella I, Asselta R, Peyvandi F. Factor XI deficiency in Southern Iran:identification of a novel missense mutation. Ann Hematol. 2009;88:359-63. (IF 2.919)

472. Palla R, Lavoretano S, Lombardi R, Garagiola I, Karimi M, Afrasiabi R, Ramzi M, De Cristofaro R, Peyvandi F. The first deletion mutation in the TSP1-6 repeat domain of ADAMTS-13 in a family with inherited thrombotic thrombocytopenic purpura. Haematologica. 2009;94:289-93. (IF 6.416)

473. Peyvandi F, Lotta LA, Mannucci PM. Inhibitors of factor VIII in hemophilia. N Engl J Med. 2009;361:309. (commentary IF 47.050:5 = 9.410)

2008

474. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica. 2008;93:232-9. (IF 5.978)

475. Mannucci PM, Peyvandi F. Thrombophilia screening: little role for the JAK2V617F mutation. Mayo Clin Proc. 2008;83:398-9. (commentary IF 4.811:5 = 0.962)

476. Margaglione M, Castaman G; Morfini M, Rocino A, Santagostino E, Tagariello G, Tagliaferri AR, Zanon E, Bicocchi MP, Castaldo G, Peyvandi F, Santacroce R, Torricelli F, Grandone E, Mannucci PM; Aice-Genetics Study Group. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica 2008;93:722-8. (IF 5.978)

477. Zhang B, Spreafico M, Zheng C, Yang A, Platzer P, Callaghan MU, Avci Z, Ozbek N, Mahlangu J, Haw T, Kaufman RJ, Marchant K, Tuddenham E, Selidsohn U, Peyvandi F, Ginsburg D. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood 2008;111:5592-600. (IF 10.432)

478. Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, Peyvandi F. Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica 2008;93:934-8. (IF 5.978)

479. Di Stasio E, Lancellotti S, Peyvandi F, Palla R, Mannucci PM, de Cristofaro R. Mechanistic studies on ADAMTS-13 catalysis. Biophys J 2008;95:2450-61. (IF 4.683)

480. Peyvandi F, Cattaneo M, Inbal A, De Moerloose P, Spreafico M. Rare bleeding disorders. Haemophilia 2008;14:202-10. (review: IF 2.394)

481. Franchini M, Peyvandi F, Mannucci PM. The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. Trends cardiovasc Med. 2008;18:157-62. (review: IF 4.121)

482. Tuddenham EG, Ingerslev J, Sorensen LN, Christiansen K, Mariani G, Peyvandi F, Waddington SN, Buckley SM, Kochanek S, Chuah MK, Vandendriessche T, Berntorp E. Genetic aspects and research development in haemostasis. Haemophilia 2008;14:113-8. (review: IF 2.394)

483. Spreafico M, Lodigiani C, van Leeuven Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics. 2008;9:1237-50. (IF 3.551)

484. Tripodi A, Peyvandi F, Chantarangkul V, Palla R, Afrasiabi A, Canciani MT, Chung DW, Ferrari S, Fujimura Y, Karimi M, kokame K, Kremer Hovinga JA, Lammle B, de Meyer SF, Plaimauer B, vanhoorelbeke K, Varadi K, Mannucci PM. Second collaborative study evaluating performancecharacteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost. 2008;6:1534-41. (IF 6.291)

485. Peyvandi F, Spreafico M. National and International registries of rare bleeding disorders. Blood Transfus. 2008;6:s45-8. (conference paper: IF -)

486. Dall'Osso C, Guella I, Duga S, Locatelli N, Paraboschi EM, Spreafico M, Afrasiabi A, Pechlaner C, Peyvandi F, Tenchini ML, Asselta R. Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. Haematologica. 2008;93:1505-13. (IF 5.978)

487. Garagiola I, Valsecchi C, Lavoretano S, Oren H, Bohm M, Peyvandi F. Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion. Haematologica. 2008;93:1678-85. (IF 5.978)

488. Plate M, Asselta R, Spena S, Spreafico M, Fagoonee S, Peyvandi F, Tenchini ML, Duga S. Congenital hypofibrinogenemia: characterization of two missense mutations affecting fibrinogen assembly and secretion. Blood Cell Mol Dis. 2008;41:292-7. (IF 2.749)

489. Maino A, Garagiola I, Artoni A, Al-Humood S, Peyvandi F. A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia. 2008;14:66. (letter IF 2.394:5 = 0.480)

490. Kalina U, Stohr HA, Bickhard H, Knaub S, Siboni SM, Mannucci PM, Peyvandi F. Rotational thromboelastography for monitorino of fibrinogen concentrate therapy in fibrinogen deficiency. Blood Coagul Fibrinolysis. 2008;19:777-83. (IF 1.398)

491. Spreafico M, Peyvandi F. Combined FV and FVIII deficiency. Hemophilia. 2008;14:1201-8. (IF 2.394)

492. Mannucci PM, Spreafico M, Peyvandi F. Genetics of warfarin response. N Engl J Med 2008;358:2743; author reply 2743-4. (commentary IF 50.017: 5 = 10.003)

493. Mannucci PM, Spreafico M, Peyvandi F. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. J Thromb Haemost. 2008;6:1450-2. (commentary IF 6.291: 5 = 1.258)

2007

494. Siboni SM, Spreafico M, Menegatti M, Martinelli I, Peyvandi F. Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis.Blood Coagul Fibrinolysis 2007;18:81-4. (IF 1.373)

495. Monaldini L, Asselta R, Duga S, Peyvandi F, Karimi M, Malcovati M, Tenchini ML. Mutational screening of six afibrinogenemic patients: Identification and characterization of four novel molecular defects. Thromb Haemost 2007;97:546-51. (IF 3.501)

496. Peyvandi F. Rare coagulation disorders: an emerging issue. Blood Transfus. 2007;5:185-6. (editorial: IF -)

497. Plate M, Asselta R, Peyvandi F, Tenchini ML, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient. Biochim Biophys Acta 2007;1772:781-7. (IF 2.371)

498. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007;138:534-40. (IF 4.490)

499. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007;5:2421-8. (IF 5.947)

500. Jayandharan G, Spreafico M, Viswabandya A, Chandy M, Srivastava A, Peyvandi F. Mutations in the MCFD2 gene are predominant among patients with hereditary combined FV and FVIII deficiency (F5F8D) in India. Haemophilia 2007;13:413-9. (IF 1.947)

501. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007;13 (Suppl. 5):65-8. (IF 1.947)

502. Afrasiabi A, Lecchi A, Artoni A, Karimi M, Ashouri E, Peyvandi F, Mannucci PM. Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran. Platelets 2007;18:409-13. (IF 1.915)

503. Mannucci PM, Peyvandi F. TTP and ADAMTS13: When Is Testing Appropriate? Hematology Am Soc Hematol Educ Program. 2007:121-6. (review: IF 1.915)

2006

504. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, Mannucci P. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood 2006;108:1280-3. (IF 10.370)

505. Zhang B, McGee B, Yamaoka JS, Guglielmone H, Downes KA, Minoldo S, Jarchum G, Peyvandi F, de Bosch NB, Ruiz-Saez A, Chatelain B, Olpinski M, Bockenstedt P, Sperl W, Kaufman RJ, Nichols WC, Tuddenham EG, Ginsburg D. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 2006;107:1903-7. (IF 10.370)

506. Zivelin A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conard J, Peyvandi F, Kyrle PA, Bertina R, Peyvandi F, Emmerich J, Seligsohn U. Prothrombin G20210A is an ancestral prothrombotic mutation that occurred in caucasians approximately 24,000 years ago. Blood 2006;107:4666-8. (IF 10.370)

507. Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannucci PM. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mut 2006;27:330-6. (IF 6.473)

508. De Cristofaro R, Peyvandi F, Baronciani L, Palla R, Lavoretano S, Lombardi R, Di Stasio E, Federici AB, Mannucci PM. Molecular mapping of the chloride binding site in von willebrabd factor (VWF): Energetics and conformational effects on the VWF/ADAMTS-13 interaction. J Biol Chem 2006;281:30400-11. (IF 5.808)

509. De Cristofaro R, Carotti A, Akhavan S, Palla R, Peyvandi F, Altomare C, Mannucci PM. The natural mutation by deletion of Lys9 in the thrombin A-chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding. FEBS J 2006;273:159-69. (IF 3.033)

510. Palmieri O, Latiano A, Valvano R, D'Inca R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, Bossa F, Zagaria C, Andriulli A, Devoto M, Annese V. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2006;23:497-506. (IF 3.287)

511. Khalife H, Muwakkit S, Al-Moussawi H, Dabbous I, Khoury R, Peyvandi F, Abboud MR. Spontaneous splenic rupture in a patient with factor XIII deficiency and a novel mutation. Pediatr Blood Cancer 2006;50:113-4. (IF 1.882)

512. Monaldini L, Asselta R, Duga S, Peyvandi F, Ghosh K, Malcovati M, Tenchini ML. Fibrinogen Mumbai: intracellular retention due to a novel G434D mutation in the Bbeta-chain gene. Haematologica 2006; 91:628-33. (IF 5.032)

513. Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya SM, Johnson MJ,Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia 2006;12 (Suppl 3):82-9. (review: IF 3.073)

514. Peyvandi F, Kaufman RJ, Seligsohn U, Salomon O, Bolton-Maggs PH, Spreafico M, Menegatti M, Palla R, Siboni S, Mannucci PM. Rare bleeding disorders. Haemophilia 2006;12 (Suppl. 3):137-42. (review: IF 3.073)

515. Peyvandi F, Siboni SM, Lambertenghi Deliliers D, Lavoretano S, De Fazio N, Moroni B, Lambertenghi Deliliers G, Mannucci PM. Prospective study on the behaviour of the metalloprotease

ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006;134:187-95. (IF 4.498)

516. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4:1510-16. (letter IF 5.138: 5 = 1.030)

517. Karimi M, Sabzi A, Peyvandi F, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. J Thromb Haemost. 2006;4:701-2. (letter IF 5.138: 5 = 1.030)

518. Karimi M, Sabzi A, Peyvandi F, Mannucci PM. Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Intern Emerg Med. 2006;1:3539. (IF -)

2005

519. Akhavan S, Miteva MA, Villoutreix BO, Venisse L, Peyvandi F, Mannucci PM, Guillin MC, Bezeaud A. critical role for Gly25 in the B chain of human thrombin. J Thromb Haemost 2005;3:139-45. (IF 5.262)

520. Mannucci PM, Lavoretano S, Peyvandi F. The thrombotic microangipathies. Blood Transfus. 2005;3:120-35. (review: IF -)

521. Mannucci PM, Bernardinelli L, Foco L, Galli M, Ribichini F, Tubaro M, Peyvandi F. Tissue plasminogen activator antigen is strongly associated with myocardial inferction in young women. J Thromb Haemost. 2005;3:280-6. (IF 5.262)

522. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, Wulff K, Schved JF, Auerswald G, Ingerslev J, Bernardi F; International factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005;93:481-7. (IF 3.056)

523. Germanos-Haddad M, de Moerloose P, Boehlen F, Peyvandi F, Neerman-Arbez M. Homozygosity for a Thr575Met missense mutation in the catalytic domain associated with factor XI deficiency. Haematologica. 2005;90:418-9. (IF 4.575)

524. De Cristofaro R, Peyvandi F, Palla R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di Stasio E, Mannucci PM. Role of chloride ions in the modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem. 2005;280:23295-302. (IF 5.854)

525. Rieger M, Mannucci PM, Hovinga JA, Herzog A, Gerstembauer G, Konetschny C, Zimmerman K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, Lammle B, Scheiflinger F. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262-7. (IF 10.131)

526. Mohanty D, Ghosh K, Shetty S, Spreafico M, Garagiola I, Peyvandi F. Mutations in the MCFD2 gene and a novel mutation in the LMAN1 gene in Indian families with combined deficiency of factor V and VIII. Am J Hematol. 2005;79:262-6. (IF 1.612)

527. Spina L, Saibeni S, Battaglioli T, Peyvandi F, De Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases:role of inherited throbophilia. Am J Gastroenterol. 2005;100:2036-41. (IF 5.116)

528. Peyvandi F, Garagiola I, Palla R, Marziliano N, Mannucci PM. Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3' untranslated region of the factor VII (FVII) gene: Molecular characterisation of patient with severe FVII deficiency. Hum Mut. 2005;26:455-61. (IF 7.923)

529. Afrasiabi A, Artoni A, Karimi M, Peyvandi F, Ashouri E, Mannucci PM. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. Clin Lab Haematol. 2005;27:324-7. (IF 0.846)

530. Peyvandi F. The role of ADAMTS13 in the new pathogenesis of TTP. Hematology. 2005;10:47-8. (IF -)

531. Lukes AS, Kadir RA, Peyvandi F, Kouides PA. Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertil Steril. 2005;84:1338-44. (IF 3.114)

532. Kouides PA, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertil Steril. 2005;84:1345-51. (IF 3.114)

533. Frasers IS, Bonnar J, Peyvandi F. Requirements for research investigations to clarify the relationships and management of menstrual abnormalities in women with hemostatic disorders.Fertil Steril. 2005;84:1360-5. (IF 3.114)

534. Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. Semin Thromb Hemost. 2005;31:544-54. (IF 2.077)

535. Peyvandi F, Bernardinelli L, Martini CH, Celli P, Mannucci PM. Factor VII gene polymorphisms are not associated with myocardial infarction in young women. J Thromb Haemost. 2005;4:803-4. (letter IF 5.262:5 = 1.052)

536. Tripodi A, Chantarangkul V, Menegatti M, Tagliabue L, Peyvandi F. Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. Clin Chem. 2005;51:1310-1. (letter IF 7.717:5 = 1.543)

2004

537. Asselta R, Duga S, Spena S, Peyvandi F, Castaman G, Malcovati M, Mannucci PM, Tenchini ML. Missense or splicing mutation? The case of a fibrinogen B-chain mutation causing severe hypofibrinogenemia. Blood. 2004;103:3051-4. (IF 9.782)

538. Menegatti M, Karimi M, Garagiola I, Mannucci P, Peyvandi F. A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency. Am J Hematol. 2004;77:90-1. (IF 1.701)

539. Peyvandi F, Tagliabue L, Menegatti M, Karimi M, Komaromi I, Katona E, Muszbek L, Mannucci PM. Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. Hum Mutat. 2004;23:98-108. (IF 6.845)

540. De Cristofaro R, Akhavan S, Altomare C, Carotti A, Peyvandi F, Mannucci PM. A natural prothrombin mutant reveals an unexpected influence of the A-chain's structure on the activity of human -thrombin. J Biol Chem. 2004;279:13035-43. (IF 6.355)

541. Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther. 2004;75:198-203. (IF 6.825)

542. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243-52. (IF 9.782)

543. Karimi M, Peyvandi F, Siboni S, Ardeshiri R, Gringeri A, Mannucci PM. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Haemophilia. 2004;10:367-9. (IF 2.078)

544. D'Andrea G, Bossone A, Lupone MR, Peyvandi F, Maisto G, Perricone F, Grandone E, Margaglione M. Molecular characterization of a factor VII deficient patient supports the importance of the second epidermal growth factor-like domain. Haematologica. 2004;89:979-84. (IF 4.192)

545. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77:198-9. (IF 1.701)

546. Spena S, Duga S, Asselta R, Peyvandi F, Mahasandana C, Malcovati M, Tenchini ML. Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen Aalpha-chain gene. Eur J Hum Genet. 2004;12:891-8. (IF 2.741)

547. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2004;127:433-9. (IF 3.195)

548. Zadra G, Asselta R, Malcovati M, Santagostino E, Peyvandi F, Mannucci PM, Tenchini ML, Duga S. Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. Haematologica. 2004;89:1332-40. (IF 4.192)

549. Peyvandi F, De Cristofaro R, Garagiola I, Palla R, Akhavan S, Landolfi R, Mannucci PM. The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency. Br J Haematol. 2004;127:576-84. (IF 3.195)

2003

550. Atherosclerosis, Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and development of acute myocardical infarction at a young age. Circulation. 2003;107:1117-22. (IF 11.164)

551. Duga S, Montefusco MC, Asselta R, Malcovati M, Peyvandi F, Santagostino E, Mannucci PM, Tenchini ML. Arg2074Cys missense mutation in the C2-domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood. 2003;101:173-7. (IF 10.120)

552. Mannucci PM, Karimi M, Mosalaei A, Canciani MT, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica. 2003;88:454-8. (IF 3.453)

553. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cell Mol Dis. 2003;30:264-70. (IF 1.991)

554. Montefusco MC, Duga S, Asselta R, Malcovati M, Peyvandi F, Santagostino E, Mannucci PM, Tenchini ML. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood. 2003;102:3210-6. (IF 10.120)

555. Asselta R, Montefusco MC, Duga S, Malcovati M, Peyvandi F, Mannucci PM, Tenchini ML. Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain. J Thromb Haemost. 2003;1:1237-44. (IF -)

556. Garagiola I, Palla R and Peyvandi F. Pitfalls in molecular diagnosis in a family with severe factor VII (FVII) deficiency-misdiagnosis by direct sequence analysis using a PCR product. Prenat Diagn. 2003;23:731-4. (IF 1.475)

557. Spena S, Asselta R, Duga S, Malcovati M, Peyvandi F, Mannucci PM, Tenchini ML. Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bbeta-chain gene. Biochim Biophys Acta. 2003;1639:87-94. (IF 2.557)

558. Mannucci PM, Peyvandi F, Ardissino D. Risk of myocardial infarction and polymorphisms in candidate genes. N Engl J Med. 2003;348:1176-7. (commentary IF 34.833:5 = 6.970)

559. Mannucci PM, Ardissino D, Merlini PA, Peyvandi F. Vagaries of genetic association studies in myocardial infarction. Blood. 2003;102:1558-9. (commentary IF 10.120:5 = 2.024)

560. Lak M, Peyvandi F, Ali Sharifian A, K. Karimi, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost. 2003;1:1852-3. (letter: IF -)

561. Spreafico M, Peyvandi F, Pizzotti D, Moia M, Mannucci PM. Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. J Thromb Haemost. 2003;1:2252-3. (letter: IF -)

2002

562. Peyvandi F, Menegatti M, Santagostino E, Akhavan S, Uprichard J, Perry DJ, Perkins SJ, Mannucci PM. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol. 2002;117:685-92. (IF 3.052)

563. Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci PM. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-A cause for concern. Thromb Haemost. 2002;88:690-1. (letter IF 4.357:5 = 0.871)

564. Peyvandi F, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica. 2002;87:512-4. (IF 3.226)

565. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia. 2002;8:308-21. (review: IF 1.113)

566. Peyvandi F, De Cristofaro R, Akhavan S, Carew JA, Landolfi R, Bauer KA, Mannucci PM. Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity. Thromb Haemost. 2002;88:750-5. (IF 4.357)

567. Spena S, Duga S, Asselta R, Malcovati M, Peyvandi F, Tenchini ML. Congenital afibrinogenemia: first identification of splicing mutations in the fibrinogen B-chain gene causing activation of cryptic splice sites. Blood. 2002;100:4478-84. (IF 9.631)

568. Al Dieri RA, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S, Hemker CH. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002;88:576-82. (IF 4.357)

569. Mannucci PM, Gringeri A, Peyvandi F, Di Paolantonio T, Mariani M. Short-term exposure to high altitude causes coagulation activation and inhibits fibrinolysis. Thromb Haemost. 2002;87:342-3. (letter IF 4.357:5 = 0.871)

570. Asselta R, Spena S, Duga S, Peyvandi F, Malcovati M, Mannucci PM, Tenchini ML. Analysis of Iranian patients allowed the identification of the first trunc.ating mutation in the fibrinogen B-chain gene causing afibrinogenemia. Haematologica. 2002;87:855-9. (IF 3.226)

571. Peyvandi F, Spreafico M, Karimi M, Zeinali S, Mannucci PM. Allele Frequency of CYP2C9 Gene Polymorphisms in Iran. Thromb Haemost. 2002;88:874-5. (letter IF 4.357:5 = 0.871)

572. Akhavan S, De Cristofaro R, Peyvandi F, Lavoretano S, Landolfi R, Mannucci PM. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood. 2002;100:1347-53. (IF 9.631)

1996-2001

573. Peyvandi F, Carew JA, Perry DJ, Hanault M, Khanduri U, Perkins SJ, Mannucci PM, Bauer KA. Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15 base pair insertion in the factor VII gene. Blood. 2001;97:960-5. (IF 9.273)

574. Asselta R, Duga S, Spena S, Santagostino E, Peyvandi F, Piseddu G, Targhetta R, Malcovati M, Mannucci PM, Tenchini ML. Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs. Blood. 2001;98:3685-92. (IF 9.273)

575. Peyvandi F, Asselta R, Mannucci PM. Autosomal recessive deficiency of coagulation factors. Rev Clin Exp Hematol. 2001;5:369-89. (review: IF -)

576. Peyvandi F, Mannucci PM, Bucciarelli P, Zeinali S, Akhavan S, Sacchi E, Merlini PA, Perry DJ. A novel polymorphism in intron 1a of the human factor VII gene (G73A): study of a healthy Italian population and of 190 young survivors of myocardial infarction. Br J Haematol. 2000;108:247-53. (IF 3.068)

577. Peyvandi F, Jenkins VP, Mannucci PM, Billio A, Zeinali S, Perkins SJ, Perry DJ. Molecular characterization and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost. 2000;84:250-7. (IF 4.372)

578. Peyvandi F, Mannucci PM, Jenkins PV, Lee A, Coppola R, Perry DJ. Homozygous 2bp deletion in the human factor VII gene: a non-lethal mutation that is associated with a complete absence of circulating factor VII. Thromb Haemost. 2000;84:635-7. (IF 4.372)

579. Tagliabue L, Duca F, Peyvandi F. Apparently dominant transmission of a recessive disease: deficiency of factor VII in Iranian Jews. Ann Ital Med Int. 2000;15:263-6. (IF -)

580. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111:1236-9. (IF 3.068)

581. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost. 2000;84:536-40. (IF 4.372)

582. Hunault M, Arbini A, Carew JC, Peyvandi F, Bauer KA. Characterization of two naturally occurring mutations in the second Epidermal Growth Factor-like domain of factor VII. Blood 1999;93:1237-44. (IF 8.782)

583. Neerman-Arbez M, Johnson KM, Morris MA, McVey JH, Peyvandi F, Nichols WC, Ginsburg D, Rossier C, Antonarakis SE, Tuddenham EGD. Molecular analysis of the ERGIC-53 gene in 35 families with combined factor V-factor VIII deficiency. Blood. 1999;93:2253-60. (IF 8.782)

584. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost. 1999;82:1207-14. (review IF 4.983)

585. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenemia. Br J Haematol. 1999;107:204-6. (IF 3.204)

586. Peyvandi F, Tuddenham EGD, Akhtari M, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Hematol. 1998:100:773-6. (IF 3.209)

587. Peyvandi F, Mannucci PM, Lak M, Abdoullahi M, Zeinali S, Sharifian R, Perry D. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Hematol. 1998;102:626-8. (IF 3.209)

588. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Hematol. 1998;103:1067-69. (IF 3.209)

589. Mannucci PM, Mari D, Merati G, Peyvandi F, Tagliabue L, Sacchi E, Taioli E, Sansoni P, Bertolini S, Franceschi C. Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. Arterioscler Thromb Vasc Biol. 1997;17:755-9. (IF 5.317)

590. Faioni EM, Merati G, Peyvandi F, Bettini P, Mannucci PM. The G1456 to T mutation in the thrombomodulin gene is not frequent in patients with venous thrombosis. Blood. 1997;89:1467. (letter IF 9.507:5 = 1.901)

591. Peyvandi F, Mannucci PM, Asti D, Abdoullahi M, Di Rocco N, Sharifian R. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Hemophilia. 1997;3:242-6. (IF 0.971)

592. Ardissino D, Peyvandi F, Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506Gln) mutation in young survivors of myocardial infarction. Thromb Haemost. 1996;75:701-2. (IF 4.267)

593. Mannucci PM, Duca F, Peyvandi F, Tagliabue L, Merati G, Martinelli I, Cattaneo M. Frequency of factor V Arg506Gln in Italians. Thromb Haemost. 1996;75:694. (letter IF 4.267:5 = 0.855)

594. Peyvandi F, Faioni EM, Moroni GA, Rosti A, Leo L, Moia M. Autoimmune protein S deficiency and deep vein thrombosis after chickenpox. Thromb Haemost. 1996;75:212-3. (IF 4.267)

Chapters in book

1. Peyvandi F and Menegatti M. I deficit rari: protrombina, FV, FV+FVIII e FX in Clinica e terapia delle malattie emorragiche e trombotiche (Piccin editore), 2018. Pag. 255; ISBN: 978-88-299-2887-3.

2. Peyvandi F and Menegatti M. Inherited Deficiencies of Coagulation Factors II, V, V+VIII, VII, X, XI, and XIII in Williams Hemostasis and Thrombosis (K Kaushansky, M Levi Eds), 1st edition 2018. Pag. 319; ISBN-13: 978-1260117080; ISBN-10: 1260117081.

3. F. Peyvandi and M. Menegatti (2016). Inherited Deficiencies of Coagulation Factors II, V, V+VIII, VII, X, XI, and XIII in Williams Hematology (K Kaushansky, MA Lichtman, JT Prchal, M Levi, OW Press, LJ Burns, MA Caligiuri, Eds), 9th edition. Pag. 2133; ISBN 978-0-07-183300-4

4. Pier M Mannucci, Flora Peyvandi and Roberta Palla (2015). Thrombotic Thrombocytopenic Purpura and Haemolytic-Uraemic Syndrome (Congenital and Acquired). p. 783-794. In POSTGRADUATE HAEMATOLOGY 7th edition, edited by A.V. HOFFBRAND, D.R. HIGGS, D.M. KEELING AND A. B. MEHTA. John Wiley & Sons, Ltd, Oxford, UK. ISBN 9781118854327

5. Flora Peyvandi and Marzia Menegatti (2015). Rare Inherited Coagulation Disorders. p. 733-742 In POSTGRADUATE HAEMATOLOGY 7th edition, edited by A.V. HOFFBRAND, D.R. HIGGS, D.M. KEELING AND A. B. MEHTA. John Wiley & Sons, Ltd, Oxford, UK. ISBN 9781118854327

6. F. Peyvandi, M. Menegatti and SM. Siboni (2015). Rare Coagulation Factor Defects in Pregnancy in Disorders of Thrombosis and Hemostasis in Pregnancy edited by H. Cohen and P. O'Brien. 2nd edition. ISBN 978-3-319-15119-9

7. Federici AB, Mannucci PM, Peyvandi F. (2015). Malattie emorragiche congenite e acquisite. p. 285-338. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERS G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. Manuale di Ematologia II Edizione. TORINO: Minerva Medica S.p.a, ISBN: 978-88-7711-816-5

8. Peyvandi F, Ferrari B, Cannavo' A, Rossio R. (2015). Microangiopatie trombotiche. p. 339-348. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERS G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. Manuale di Ematologia II Edizione. TORINO: Minerva Medica S.p.a, ISBN: 978-88-7711-816-5

9. Flora Peyvandi and Marzia Menegatti (2014). Factor V and combined Factor V and VIII deficiencies. p. 403-412. In TEXTBOOK OF HEMOPHILIA, 3rd edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Blackwell Publishing Ltd. ISBN 978-1-118-39824-1

10. Flora Peyvandi, Marzia Menegatti and Simona Maria Siboni (2012). Inherited Bleeding Disorders in Pregnancy: Rare Coagulation Factor Defects. p 131. in DISORDERS OF THROMBOSIS AND HEMOSTASIS IN PREGNANCY edited by H. COHEN AND P. O'BRIEN. ISBN 978-1-4471-4410-6, ISBN 978-1-4471-4411-3

11. Pier M Mannucci, Flora Peyvandi and Roberta Palla (2010). Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). p. 860-871. In POSTGRADUATE HAEMATOLOGY 6th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM, A.R. GREEN. Wiley-Blackwell. ISBN 9781405191807

12. Flora Peyvandi and Marzia Menegatti (2010). Rare bleeding disorders. P. 813-838. In POSTGRADUATE HAEMATOLOGY 6th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM, A.R. GREEN. Wiley-Blackwell. ISBN 9781405191807

13. Flora Peyvandi and Marta Spreafico (2010). Factor V and combined Factor V and VIII deficiencies. P. 332-340. In TEXTBOOK OF HEMOPHILIA, 2nd edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Wiley-Blackwell. ISBN 9781405169141

14. Flora Peyvandi (2009). Rare Bleeding Disorders. p. 54-64. In INHERITED BLEEDING DISORDERS IN WOMEN, 1st edition, by CHRISTINE A. LEE, REZAN A. KADIR AND PETER A. KOUIDES. Wiley-Blackwell. ISBN 978-1-4051-6915-8

15. Federici AB, Mannucci PM, Peyvandi F. (2008). Patologie della coagulazione. p. 229-279. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERS G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. Manuale di Ematologia. TORINO: Minerva Medica S.p.a, ISBN/ISSN: 10: 88-7711-618-8

16. Peyvandi F, Lavoretano S, Palla R. (2008). Microangiopatie trombotiche. p. 281-288. In: CORRADINI P; FOA R; BOCCADORO M; CAPPELLINI MD; CARLO-STELLA C; CATTANEO M; FEDERICI AB; GAMBACORTI-PASSERINI C; LAMBERTENGHI DELILIERS G; MANNUCCI PM; PANE F; PEYVANDI F; POGLIANI EM. Manuale di Ematologia. TORINO: Minerva Medica S.p.a, ISBN/ISSN: 10: 88-7711-618-8

17. Pier M Mannucci and Flora Peyvandi (2005). Thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome (congenital and acquired). p. 876-884. In POSTGRADUATE HAEMATOLOGY 5th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM. Blackwell Publishing Ltd. ISBN 9781405191807

18. Flora Peyvandi and Pier M Mannucci (2005). Congenital bleeding: autosomal recessive disorders. p. 842-858. In POSTGRADUATE HAEMATOLOGY 5th edition, edited by A.V. HOFFBRAND, D. CATOVSKY, E.G.D. TUDDENHAM. Blackwell Publishing Ltd. ISBN 9781405191807

19. Flora Peyvandi and Marta Spreafico (2005). Factor V and combined Factor V and VIII deficiencies. p. 306. In TEXTBOOK OF HEMOPHILIA, 1st edition, edited by CHRISTINE LEE, ERIK BERNTORP, KEITH HOOTS. Blackwell Publishing Ltd. ISBN 1405127694

20. Stefano Duga, Rosanna Asselta, Elena Santagostino, Flora Peyvandi, Maria Luisa Tenchini, Pier Mannuccio Mannucci (2004). Coagulopatie ereditarie. p. 381-410. In MALATTIE GENETICHE - MOLECOLE E GENI - DIAGNOSI, PREVENZIONE E TERAPIA edited by CAO A, DALLAPICCOLA B AND NOTARANGELO LD. Piccin Nuova Libraria. ISBN: 978-88-299-1652-8

21. David Perry and Flora Peyvandi (1999). Detection of DNA by silver staining. p. 63-9. In HEMOSTASIS AND THROMBOSIS PROTOCOLS: METHODS IN MOLECULAR MEDICINE. Edited by DAVID J. PERRY AND JOHN K. PASI. Humana Press. ISBN 978-0896034198

Non peer-reviewed publications

1. Patients Informative Booklet on the Establishment of a European Network of Rare Bleeding Disorders (EN-RBD) project funded by EC (downloadable at www.rbdd.eu) (2011), by F. Peyvandi, R. Palla, M. Menegatti, S. Malosio.

2. F. Peyvandi, A. Cairo, R. Palla, M. Menegatti. Registri nazionali ed internazionali sulle malattie rare della coagulazione. Focus Emostasi Anno 4 - N. 1 - Febbraio 2011. Four-monthly magazine edited by Alter M&P S.r.l., Milan, Italy.

3. Peyvandi F, Palla R, Menegatti M. (2008). Rare coagulation defects. Yearbook 2008 - Highlights of XXVIII International Congress of Haemophilia. p. 40-45 AICEcongressi.

4. Patients Informative Booklet on the Women with rare bleeding disorders project (2007), by F. Peyvandi, M. Spreafico, R. Palla, S. Lavoretano, I. Garagiola, S.M. Siboni.

5. Patients Informative Booklet. Dalla diagnosi di portatrice di Emofilia alla diagnosi prenatale (downloadable at www.aiceonline.it/documenti/genetica/diagnosiportatrice.pdf), by F. Peyvandi, L. Tagliabue, M. Menegatti, I. Garagiola, E. Santagostino. Edited by Associazione Italiana Centri Emofilia (AICE).

Projects

GRANTED PROJECTS

2019 Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity. MSCA-ITN-(ETN) H2020-MSCA-ITN-2019 (Beneficiary, 48 months)

2018 Identification of novel genetic risk factors located in the conserved haplotype region surrounding the LCT locus on chromosome 2q21. Ricerca Finalizzata, Italian Ministry of Health, Rome, Italy (Principal Investigator, 36 months)

2018 Inhibitor development in previously untreated patients with severe hemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product:an international, multicenter, prospective, controlled, randomized, open label, clinical trial, SIPPET 2. Agenzia Italiana del Farmaco, bando Ricerca Indipendente, Rome, Italy (Principal Investigator, 36 months)

2017 RBDD-PLG project; international retrospective and prospective study of individuals affected with hypoplasminogenemia. Indiana Hemophilia & Thrombosis Center, indianapolis, IN, USA

(Co-Principal Investigator, 36 months)

2017 High throughput anlaysis of antibody binding prophiles in previously severe haemophilia A. Grifols Investigator Sponsored Research (Principal Investigator, 24 months)

2016

Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and Comprehensive Care Centers in Iran: Pediatric Congenital Bleeding Disorder Research Center, Mofid Children's Hospital, Tehran, Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)

2013 Diagnosi prenatale: l'uso delle cellule fetali per la diagnosi genetica non invasiva in donne portatrici di emofilia. Italo Monzino Foundation, Milan - Italy (Principal Investigator, 36 months)

2013 Microangiopatie trombotiche. Italo Monzino Foundation, Milan - Italy (Principal Investigator, 36 months)

2013 Influence of aggregation extent of FVIII in pharmaceutical concentrates on their biochemical properties and coagulant efficacy. Funded by Biotest AG (Principal Investigator, 24 months)

2012

Costituzione di una rete lombarda per lo studio e il trattamento dei pazienti sottoposti a procedure di aferesi terapeutica. Regione Lombardia, Direzione generale Sanita - Italy (Partner, 24 months)

2012

Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and Esfahan Hemophilia center, Sayedalshohada Hospital, Esfahan - Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)

2012 European Haemophilia Network (EUHANET). Commission of the European Union, The Executive Agency for Health and Consumers (EAHC) (Workpackage leader, 36 months)

2012 Prospective evaluation of the intensity of bleeding episodes in patients with coagulation factor XIII deficiency (PRO-RBDD). Funded by NovoNordisk, Denmark (Principal Investigator, 72 months)

2011 New risks factor for complex atherothrombotic diseases - role of von Willebrand factor and of the metalloprotease ADAMTS13. Fiera Foundation, Milan - Italy (Principal Investigator, 17 months out of 72)

2011 Discovery of genetic determinants of inhibitor development in hemophilia a by exome sequencing. Bayer Hemophilia Awards Program - Special project award (Principal Investigator, 24 months)

2011 Biochemical, conformational and functional characterization of a novel purified FVIII concentrate from BioTest: a comparative study. Funded by Biotest AG (Principal Investigator, 24 months)

2011 Multiplexed next-generation sequencing of the haemostatic exome in deep vein thrombosis. Cariplo Foundation, Milan - Italy (Principal Investigator, 21 months)

2010 Modello di integrazione tra attivita' di ricerca sperimentale e pratica clinica: l'approccio alle microangiopatie trombotiche. Regione Lombardia, Direzione generale Sanita - Italy (Partner, 24 months)

2010 Microangiopatie trombotiche. Italo Monzino Foundation, Milan - Italy (Collaborator, 36 months)

2010 Enlargement of the European network of the Rare Bleeding Disorders (EN-RBD). European Association of Hemophilia and Allied Disorders (EAHAD), Sheffield - UK (Principal Investigator, 12 months)

2010 Programma di lavoro del Presidio di coordinamento regionale per le coagulopatie congenite. Regione Lombardia, Direzione generale Sanita - Italy (Principal Investigator, 36 months)

2009 Inhibitor development in previously untreated patients (PUPs) or minimally blood component-treated patients (MBCTPS) when exposed to von Willebrand factor-containing factor VIII concentrates and to recombinant factor VIII concentrates: an international, multicentre, prospective, controlled, randomised, open label, clinical trial. Angelo Bianchi Bonomi Foundation, Milan - Italy (Partner, 72 months)

2009 Cellule fetali nel sangue materno. Una promettente tecnica non invasiva di diagnosi prenatale delle malattie genetiche. Paracelso Foundation, Milan - Italy (Principal Investigator, 12 months)

2009 Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan - Italy (Principal Investigator, 36 months)

2008 Determinazione del sesso fetale nel I0 trimestre di gravidanza mediante tecniche non

invasive. PUR (ex FIRST) grant, University of Milan, Milan - Italy (Principal Investigator, 12 months)

2008 Menorrhagia and other gynecological problems in women affected by rare bleeding disorders. Laboratoire francais du Fractionnement et des Biotechnologies (LFB) - France (Principal Investigator, 12 months)

2007

Establishment of a European Network of Rare Bleeding Disorders. Istituto Superiore di Sanita, Rome - Italy (Principal Investigator, 24 months)

2007

Meccanismi molecolari patogenetici nella carenza combinata dei fattori della coagulazione V e VIII (F5F8D). FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)

2007

Biochemical and molecular characterization of the interaction between Von Willebrand Factor and ADAMTS-13: new hypotheses on physiopathogenesis of thrombotic microangiopathic diseases. PRIN grant, Italian Ministry of University and Research - Italy (Principal Investigator, 24 months)

2007 Establishment of an European Network of Rare Bleeding Disorders. Commission of the European Unit - Public Health Executive Agency (PHEA) (Principal Investigator, 36 months)

2007 Rare bleeding disorders: development of a European Registry and characterization of the molecular mechanisms. Telethon - Italy (Collaborator, 36 months)

2007 Thrombospondin-1 (TSP-1), ADAMTS13 and von Willebrand (VWF): role in the thrombotic thrombocytopenic purpura (TTP). Funded by Baxter - Italy (Principal Investigator, 12 months)

2006 Trombospondina-1 (TSP-1), ADAMTS13 e fattore di von Willebrand (VWF): ruolo nella porpora trombotica trombocitopenica (TTP). FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)

2006 Markers genetici nella prevenzione farmacologica dell'ictus ischemico giovanile. Ricerca Finalizzata Ministry of Health - Italy (Collaborator, 24 months)

2006 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and Hemostasis & Thrombosis unit, Hematology research center, Dastgheyb Hospital, Shiraz medical University of Science, Shiraz - Iran, World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)

2006 Mantenimento ed implementazione di un Database Internazionale sulle malattie rare della coagulazione. Banca Fideuram (Principal Investigator, una tantum)

2005 Registro Internazionale sui pazienti affetti da Porpora Trombotica Trombocitopenica (TTP): caratterizzazione fenotipica e genotipica. FIRST grant, University of Milan- Italy (Principal Investigator, 12 months)

2005 Determinazione del sesso fetale nel I° trimestre di gravidanza mediante tecniche non invasive. Italo Monzino Foundation, Milan - Italy (Principal Investigator, 36 months)

2005 Molecular genetics of hereditary rare bleeding disorders in Indian population. Ministry of Foreign Affairs, General Directorate for Cultural Promotion and Co-operation - Italy (Principal Investigator, 24 months)

2004 Association between polymorphisms in gene encoding for inflammaton protein and juvenile myocardial infarction. COFIN grant, Italian Ministry of University and Research - Italy (Collaborator, 24 months)

2004

Sviluppo di nuovi test diagnostici quantitativi e funzionali della proteasi del fattore von Willebrand per la diagnosi delle malattie trombotiche microangiopatiche. IRCCS Maggiore Hospital, Milan - Italy (Principal Investigator, 12 months)

2003 Valutazione di polimorfismi genetici associati alla trombosi e farmacogenomica degli anticoagulanti con nuove tecnologie ad alta resa. IRCCS Maggiore Hospital, Milan - Italy (Principal Investigator, 12 months)

2003 Inflammation genes and development of myocardial infarction at a young age. Retrospective case-control study of 2000 cases and 2000 controls enrolled by 125 Italian Coronary Care Unit in eight years. Cariplo Foundation, Milan - Italy (Principal Investigator, 12 months)

2003 Phenotype and genotype characterization of recessively inherited coagulation disorders. Bayer Hemophilia Awards Program - Early career investigator award. (Principal Investigator, 24 months)

2003 Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. Telethon - Italy (Collaborator, 36

months)

2003 Clinical and molecular diagnosis of rare coagulation disorders. UniCredit Private Bank (Principal Investigator, una tantum)

2003 Membrane metalloproteinases involved in disorders of haemostasis. COFIN grant, Italian Ministry of University and Research - Italy (Collaborator, 24 months)

2002

Quantitative and functional assays of the VWF-cleaving protease (ADAMTS-13) for thrombotic thrombocytopenic purpura. Cariplo Foundation, Milan - Italy (Principal Investigator, 12 months)

2002 Rare inherited coagulation disorders: clinical and molecular characterization to develop a National Registry and molecular tests for prenatal diagnosis. COFIN grant, Italian Ministry of University and Research - Italy (Collaborator, 24 months)

2002

Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and Nemazee Hospital, Shiraz - Iran. World Federation of Hemophilia (WFH) (Principal Investigator, 48 months)

2001

In vivo and in vitro studies of angiogenetic process by VEGF in patients by myocardial infarction. Cariplo Foundation, Milan - Italy (Principal Investigator, 12 months)

2001 Difetti autosomici recessivi della coagulazione del sangue: causa di carenza di fattori della coagulazione. Italo Monzino Foundation, Milan - Italy (Principal Investigator, 24 months)

2000 Hemophilia Treatment Centre Twinning Programme between the Hemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Milan - Italy and the Teheran Iman Khomeini Hospital Hemophilia Center, Tehran - Iran, awarded by World Federation of Hemophilia (WFH) (Principal Investigator, 36 months)

2000 Diagnosi prenatale e precoce delle malattie ereditarie. Ricerca Finalizzata Ministry of Health - Italy (Principal Investigator, 12 months)

1998 Caratterizzazione molecolare della carenza della carenza di fattore X della coagulazione. Bando giovani ricercatori, University of Milan - Italy (Principal Investigator, 24 months)

Memberships

Scientific societies/academy and patients associations:

International Society of Thrombosis and Haemostasis (ISTH)

2020 - 2022 President-Elect

2020 - present Member of the Scientific Program Committee Task Force

2019 - present Member of the World Hemophilia Gene Therapy Registry Executive Committee

2018 - present Chairman of the Education and Outreach Committee

2018 - present Member of the Executive Committee

2016 - present Elected member of the ISTH Council

2016 - present Member of the Guidelines and Guidance Committee

2010 -2014 Chair of the of the Scientific and Standardization Committee on Factor VIII, Factor IX & Rare Coagulation Disorders

World Federation of Hemophilia (WFH)

2018 - present Member of the VWD & Rare Bleeding Disorders Committee

2018 - present EHC Liaison Medical Advisory Board

2016 - present Member of the Coagulation Product Safety, Supply and Access (CPSSA) Committee

2016 - 2018 Chair of the Education Advisory Committee and member of the Humanitarian Aid Committee

2014 - 2018 Member of the Board of Directors and of the Medical Advisory Board

2012 - 2018 Chair of the VWD & Rare Bleeding Disorders Committee

2012 -2015 Member of the International Hemophilia Training Centre (IHTC) Committee

European Association for Haemophilia and Allied Disorders (EAHAD)

2022 - 2024 Past-President of the Executive Committee

2020 - 2022 President of the Executive Committee

2018 - 2020 Vice-President of the Executive Committee

2015 - present Member of the Executive Committee

European Haemophilia Consortium (EHC)

2019 - 2020 Chairperson of the Medical Advisory Group

2012 - 2018 Member of the Medical Advisory Group

EMA/Advisory Committee Experience

- 07/06/2019: European Symposium Optimal Treatment of Haemophilia, Wildbad Kreuth Initiative V (EDQM, EP, PEI, University Munich)

- 08/06/2018: EMA Haemophilia Registries Workshop

- 08/02/2017: Presentation on Factor VIII Art.31 referral to PRAC

- 28/11/2016: Ad hoc expert group (SAG) for the treatment of haemophilia A and haemophilia B

- 02/07/2015: EMA Haemophilia Registries Workshop

- 29/11/2013: EMA-EDQM workshop on potency assays

- Nov 2013: inclusion in the EMA experts database team

Others

2018 - present Italian Ministry of Health: Member of the Technical Health Committee - Health Research Section

2015 - present Member of the Board of the Foundation for the European Congress on Thrombosis and Haemostasis

2015 -2017 Member of the Awards Committee of the American Society of Hematology (ASH)

Other Relevant Information

Organisation of international conferences

2019: Chair of the Joint BIC & INHIBITORS International Conference 2019 Organising and Scientific Committee, Genoa, Italy

2018: Co-President of the 2020 ISTH congress, Milan, Italy

2018: Chair of the 2nd International Conference on Inhibitors in Coagulation disorders (Inhibitors2018) (Milan, Italy)

2018: Board of the 2018 European Congress on Thrombosis and Haemostasis (Marseille, France)

2017: Co-chair of the 9th BIC International Conference Organising Committee (Rome, Italy)

2017: Member of the Hemorrhagic Disorders, Hemophilia Scientific Topic Program Subcommittee for the XXVI ISTH Congress

2016: Board of the 2016 European Congress of Thrombosis and Haemostasis (The Hague, The Netherlands)

2016: Chair of the International Conference on Inhibitors in Hemophilia A (Milan, Italy)

2014: Co-chair of the 8th BIC International Conference Organising Committee (Bari, Italy)

2013: Member of the International Advisory Board for the XXIV ISTH congress

2007: Member of the Scientific Program Committee of European Hematology Association (EHA)

2007, 2008 and 2010: Organiser of the three workshops of the Establishment of a European Network of Rare Bleeding Disorders (EN-RBD) working group, in the framework of the Public Health Programme, held in Milan, Italy; Copenhagen, Denmark and Athens, Greece

Leadership in industrial innovation or design

- Close collaboration and consulting activities with Kedrion Biopharma, Barga (LU), Italy for the development of the first plasma-derived factor V product for patients with factor V deficiency and of plasminogen plasma-derived eye drops for patients affected with plasminogen deficiency.

- Clinical leadership in developing and conducting a clinical trial in collaboration with Ablynx, Ghent, Belgium, to test the efficacy of a new drug for the treatment of patients with thrombotic thrombocytopenic purpura, an ultra-rare, acute, life-threatening blood clotting disorder. This drug has demonstrated the potential to become an important new component in the standard of care for thrombotic thrombocytopenic purpura (TTP).